

Joshi J. Alumkal, MD
Professor of Internal Medicine
Rogel Cancer Center, Room 7312
1500 E. Medical Center Drive
Ann Arbor, MI 48109
Phone: 734-936-9868
Fax: 734-647-9480
Email: jalumkal@med.umich.edu

Education and Training

Education

08/1990-05/1994 BA, Summa Cum Laude, University of Texas at Austin, Austin, TX
08/1994-05/1998 MD, Baylor College of Medicine, Houston, TX

PostDoctoral Training

07/1998-06/2001 Residency, Internal Medicine, UT-Southwestern Medical Center, Dallas, TX
07/2001-06/2002 Chief Resident, Internal Medicine, UT-Southwestern Medical Center, Dallas, TX
07/2002-12/2006 Fellowship, Oncology, Johns Hopkins University School of Medicine, Baltimore, MD

Certification And Licensure

Certification

08/2019-08/2021 ABIM - Medical Oncology #207925
08/2019-08/2021 ABIM - Internal Medicine #207925

Licensure

12/2006-08/2019 State of Oregon, Medical License
08/2019-12/2024 State of Michigan, Medical License

Academic, Administrative, Clinical, Research and Military Appointments

Academic Appointments

07/2001-06/2002 Assistant Instructor, UT-Southwestern Medical Center, Dallas, TX
01/2007-06/2014 Assistant Professor, Oregon Health & Science University, Portland, OR
01/2010-06/2014 Assistant Professor of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR
01/2011-07/2019 Faculty Appointment in the Program in Molecular & Cellular Biosciences Graduate Training Program, Oregon Health & Science University, Portland, OR
07/2014-07/2019 Associate Professor of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR
07/2014-07/2019 Associate Professor of Internal Medicine, Oregon Health & Science University, Portland, OR
07/2019 Professor of Molecular & Medical Genetics, Oregon Health & Science University, Portland, OR (Tenured)
07/2019 Professor of Internal Medicine, Oregon Health & Science University, Portland, OR
08/2019-present Professor of Internal Medicine, University of Michigan, Ann Arbor, MI (Tenured)
01/2020-present Faculty Appointment, Cancer Biology Doctoral Program, University of Michigan, Ann Arbor, MI

Administrative Appointments

01/2013-07/2019 Co-Leader, Prostate Cancer Research Program, Oregon Health & Science University, Portland, OR
01/2015-07/2019 Member, Oregon Center for Spatial Systems Biomedicine (OCSSB), Oregon Health & Science University, Portland, OR

01/2017-07/2019	Named Wayne D. Kuni & Joan E. Kuni Endowed Chair for Prostate Cancer Research, Oregon Health & Science University, Portland, OR
08/2019-present	Section Head of Prostate and Genitourinary Oncology; Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
08/2019-present	Associate Division Chief of Basic Research, Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
08/2019-present	Director of Epigenetic Therapy, Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI
08/2019-present	Member, Developmental Therapeutics Program, Rogel Cancer Center, University of Michigan, Ann Arbor, MI
01/2020-present	Member, Center for RNA Biomedicine, University of Michigan, Ann Arbor, MI
01/2020-present	Member, Cancer Biology Training Program, University of Michigan, Ann Arbor, MI
10/2020-present	Co-Leader, Translational and Clinical Research CCSG Program, Rogel Cancer Center, University of Michigan, Ann Arbor, MI
01/2021-present	Member, Center for Cell Plasticity and Organ Design, University of Michigan, Ann Arbor, MI

Grants

Current Grants

Clarifying Tumor and Microenvironmental Determinants of Enzalutamide Resistance National Comprehensive Cancer Network (NCCN)/ Astellas Pharma Global Development

Alumkal, PI

10/2021-09/2024. \$500,000

Single cell profiling to identify mechanisms of tumor progression in metastatic prostate cancer Prostate Cancer Foundation

Alumkal, PI

09/2021-08/2023. \$1,000,000

Targeting TRIM29 to Reverse Immune Checkpoint Inhibitor Resistance in Bladder Cancer Damon Runyon Cancer Research F- 21-PAF04747

Co-I without Effort (Principal Investigator: Phillip Lee Palmbo)

07/2021-06/2024. \$600,000

Assessing the effects of lighting interventions on fatigue in three populations of cancer patients NIH- 20-PAF07198

Co-I with Effort (Principal Investigator: Tewari, Muneesh)

09/2020-08/2022. \$800,031

R01CA251245: Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain Inhibition NIH

Alumkal, Joshi, PI

09/2020-08/2025. \$2,343,969

P50CA186786: Clarifying the Role of LSD1 in Neuroendocrine Prostate Cancer NIH

Joshi, Alumkal, PI

09/2020-08/2023. \$1,170,000

PC190147: Targeting LSD1 in Neuroendocrine Prostate Cancer DOD

Joshi, Alumkal, PI

09/2020-06/2023. \$1,170,000

Targeting critical determinants of a lethal prostate cancer stem cell program University of Michigan

Alumkal, Joshi, PI

04/2020-03/2022. \$150,000

2 P50 CA186786-07S1: Michigan Prostate SPORE NIH- 19-PAF00149; 20-PAF02244

Co-I with Effort (Principal Investigator: Arul M Chinnaiyan)

09/2019-08/2024. \$10,268,218

Targeting Emerging Vulnerabilities in AR-Independent Prostate Cancer SubK-NIH-DHHS-US- 19-PAF08025
Co-I with Effort (Principal Investigator: Nelson, Peter)
09/2018-08/2023. \$582,850

5P30CA46592: Cancer Center Support Grant NIH
Co-I with Effort (Principal Investigator: Fearon)
06/2018-05/2023. \$35,469,208

Submitted Grants

FOXA1 Epigenetic Mechanisms in Salivary Duct Carcinoma NIH-DHHS-US- 21-PAF04264
Co-I without Effort (Principal Investigator: Udager, Aaron Mark)
10/2021-09/2026. \$2,735,526

Delineating class-specific pathobiology and therapeutic vulnerabilities of FOXA1-altered prostate cancers Prostate Cancer Foundation- 21-PAF06667
Co-I without Effort (Principal Investigator: Parolia, Abhijit)
09/2021-08/2024. \$225,000

Past Grants

BEA-17 Effects in Prostate Cancer Beactica Therapeutics AB- 21-PAF08374
Alumkal, Joshi, PI
07/2021. \$8,886

Molecular Landscape of Prostate Cancer OHSU Knight CEDAR
Co-I (Principal Investigator: Lusardi, Alumkal)
01/2018-05/2019. \$129,058

Clinical Consortium Award – Clinical Research Site US Army Medical Rsch Acquisition Activity
Co-I (Principal Investigator: Beer)
09/2017-07/2019. \$797,822

Phase I Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ZEN003694-002) Zenith Epigenetics Ltd
Alumkal, PI
03/2017-07/2019. \$36,091

A Phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GS-5829 as a single agent in combination with enzalutamide in subjects with metastatic castrate-resistant prostate cancer Gilead Sciences Inc
Alumkal, PI
02/2017-07/2019. \$16,304

The role of LSD1 in lethal neuroendocrine prostate cancer The Anna Fuller Fund
Alumkal, PI
02/2017-02/2018. \$130,000

Targeting CREB1 in Enzalutamide-Resistant, Lethal Prostate Cancer OHSU Knight Cancer Institute
Alumkal, PI
01/2017-12/2018. \$50,000

Clarifying Mechanisms of BET Bromodomain Inhibitor Response in Castration-Resistant Prostate Cancer US Army Medical Rsch Acquisition Activity
Alumkal, PI
09/2016-09/2019. \$375,000

OHSU Center for Specialized Data Analysis as part of the GDAN NIH/NCI
Co-I (Principal Investigator: Spellman, Margolin)
09/2016-07/2019. \$330,000

Targeting AR-Independent Mechanisms of Prostate Cancer Progression with BET Bromodomain Inhibition Hope Foundation
Alumkal, PI
06/2016-05/2018. \$200,000

A Phase I Safety and Tolerability Study of ZEN003694 as a Single Agent in Patients with Metastatic Castration-resistant Prostate Cancer (ZEN003694-001) Zenith Epigenetics Corp
Alumkal, PI
04/2016-04/2019. \$251,461

Targeting AR-Independent Prostate Cancer with BET Bromodomain Inhibition Fred Hutchinson Cancer Rsch Ctr - PNW Prostate Cancer SPORE Pilot Award
Nelson, PI
03/2016-08/2017. \$50,000

Targeting Gene Activation by AR-Transcript Variants in Castration-Resistant Prostate Cancer Specific Aims: Develop new and more effective treatments for men with CRPC. ZERO – The End of Prostate Cancer
Alumkal, PI
07/2015-06/2016. \$41,558

Clinical Consortium Award – Clinical Research Site US Army Medical Rsch Acquisition Activity
Co-I (Principal Investigator: Beer)
09/2014-09/2017. \$192,966

The role of LSD1 in the evolution of castration-resistant prostate cancer NIH/NCI
Alumkal, PI
07/2014-06/2019. \$1,031,593

Bromodomain inhibition for the treatment of lethal, castration-resistant prostate cancer NIH, OCTRI Catalyst Award
Alumkal, PI
07/2014-06/2016. \$98,772

Genetic variation in evolving prostate cancers as they develop enzalutamide resistance Pilot Project-Ann P. Follansbee Estate
Alumkal, Spellman, Co-PI
07/2014-06/2015. \$50,000

Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment Clinical Trial Astellas Scientific & Medical Affairs Inc
Alumkal, PI
06/2014-07/2019. \$410,800

The role of histone demethylation in LSD1-induced gene activation Fred Hutchinson Cancer Rsch Ctr - PNW Prostate Cancer SPORE
Nelson, PI
04/2014-08/2015. \$50,000

Targeting LSD1 in Prostate Cancer Fred Hutchinson Cancer Rsch Ctr - PNW Prostate Cancer SPORE
Nelson, PI
09/2013-08/2018. \$702,779

Identifying and targeting MDV3100 resistance mechanisms in prostate cancer US Army Medical Rsch Acquisition Activity
Alumkal, PI
09/2013-09/2017. \$346,871

The Role of LSD1 in the Evolution of Castration-Resistant Prostate Cancer NIH, OCTRI Strategic Investment Award
Alumkal, PI
07/2013-06/2015. \$20,000

Identifying Acquired Tumor-Intrinsic MDV3100 Resistance Mechanisms in Prostate Cancer OHSU Knight Cancer Institute, Pilot Award
Alumkal, PI
07/2013-06/2014. \$50,000

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer Aragon Pharmaceuticals Inc
Alumkal, PI
02/2013-07/2019. \$273,683

Targeting Adaptive Pathways in Metastatic Castration Resistant Prostate Cancer Univ of California, San Francisco
Other (Principal Investigator: Small)
01/2013-12/2016. \$1,102,541

ROR1 as a Therapeutic Target in Acute Lymphoblastic Leukemia NIH/NCI
Other (Principal Investigator: Tyner)
09/2012-08/2015. \$484,170

Phase I, Open-Label, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Patients w/Metastatic Castration-Resistant Prostate Cancer AstraZeneca LP
Alumkal, PI
07/2012-07/2015. \$26,166

Identifying LSD1 network in prostate cancer Fred Hutchinson Cancer Rsch Ctr - PNW Prostate Cancer SPORE
Alumkal, PI
01/2012-08/2012. \$40,000

An Open-Label, Phase 1/2 Safety, Pharmacokinetic, and Proof-of-Concept Study of ARN-509 in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Aragon Pharmaceuticals Inc
Alumkal, PI
11/2011-07/2019. \$302,256

A Phase II Study of BKM120 in Men with Metastatic Castration-Resistant Prostate Cancer Duke University
Alumkal, PI
11/2011-06/2016. \$58,277

Overcoming LSD1-driven prostate cancer Prostate Cancer Foundation
Alumkal, PI
11/2011-11/2014. \$225,000

Using Interactome Knowledge to Identify Androgen Independent Survival Pathways and Guide Prostate Cancer Treatment Medical Research Foundation of Oregon
Co-I (Principal Investigator: Bankead)
09/2011-08/2012. \$21,800

Scholar Award Wayne D. Kuni and Joan E. Kuni Foundation
Alumkal, PI
07/2011-06/2013. \$190,000

Overcoming androgen-independent prostate cancer Fred Hutchinson Cancer Rsch Ctr - PNW Prostate Cancer SPORE
Alumkal, PI
06/2011-08/2011. \$35,000

A Phase 2, Multicenter Evaluation of 18F-fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men with Castration-Resistant Prostate Cancer and Bone Metastases American College of Radiology
Alumkal, PI
08/2010-12/2012. \$7,102

A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, with Temozolomide in Patients with Metastatic Castration Resistant Prostate Cancer Who Have Failed up to Two Non-hormonal Systemic Therapies Abbott Laboratories
Alumkal, PI
04/2010-04/2013. \$30,300

The effects of sulforaphane dose escalation in men with recurrent prostate cancer Wayne D. Kuni and Joan E. Kuni Foundation, Clinical Trial Award
Alumkal, PI
04/2010-03/2013. \$250,000

A Phase 2 Multicenter Open Label Study Evaluating the Safety and Efficacy of TAK-700 in Patients with Nonmetastatic Castration Resistant Prostate Cancer (CRPC) and a Rising Prostate Specific Antigen (PSA) Millennium Pharmaceuticals Inc
Alumkal, PI
03/2010-01/2016. \$79,507

Phase I/II Randomized Trial of LBH589 (Panobinostat) at Two Dose Levels Combined with Bicalutamide (Casodex) in Men with Castration-Resistant Prostate Cancer in a clinical setting New York University
Alumkal, PI
02/2010-06/2015. \$145,067

Prostate Cancer OCTRI Pilot Oregon Clinical & Translational Research Institute
Alumkal and Weinmann, PI
12/2009-06/2011. \$39,328

A Phase II Trial of Genomic Guided Therapy with Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer Duke University
Alumkal, PI
07/2009-12/2014. \$88,000

A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously treated Castrate Resistant Prostate Cancer Amgen Inc
Alumkal, PI
04/2009-03/2013. \$123,538

Elucidation of Novel Mechanisms of Sulforaphane Chemoprevention in a Murine Model of Prostate Cancer Fred Hutchinson Cancer Rsch Ctr - PNW Prostate Cancer SPORE
Alumkal, PI
02/2009-12/2010. \$50,000

The prostate cancer hypermethylome: Of models and men OHSU Cancer Institute
Alumkal, PI
07/2008-06/2010. \$50,000

An open label, single arm, Phase Ib dose finding study of i.v. panobinostat with docetaxel& prednisone in patients w/ hormone refractory prostate cancer Novartis Pharmaceuticals Corporation
Alumkal, PI
06/2008-01/2013. \$90,358

Ph II Single Arm, OL Study of IMC-A12 in Asymptomatic, Chemotherapy-Naïve Pts w/ Metastatic Androgen-Independent Prostate Cancer ImClone Systems Corporation
Alumkal, PI
11/2007-09/2014. \$373,589

Elucidation of Clinically Significant Mechanisms of Gene Silencing OCTRI KL2 Career Development Award
Alumkal, PI
06/2007-09/2011. \$715,778

Epigenetic Therapies in Prostate Cancer: Identification of the Epigenome and Translation into Clinical Practice
Medical Research Foundation
Alumkal, PI
06/2007-05/2008. \$30,000

Towards a better understanding of prostate cancer through epigenetics Flight Attendant Medical Research Institute
Alumkal, PI
01/2007-06/2012. \$430,070

Honors and Awards

International

1991-1994	Beta Beta Beta (Biological Honor Society)
1994	Phi Beta Kappa
1997	American Society of Hematology Summer Research Fellowship
2001	European School of Internal Medicine Delegate
2003	AACR Molecular Biology in Clinical Oncology Scholarship Recipient
2004-2005	ASCO Young Investigator Award: "DNA Methylation as a Predictor of Biochemical Recurrence after Radical Prostatectomy"
2010	Associate Scientific Advisor, Science Translational Medicine (a publication of AAAS and Science Magazine)

National

1992-1994	Alpha Epsilon Delta (Premedical Honor Society)
2005	NIH Clinical Loan Repayment Program Recipient
2006	Madison Who's Who
2014	Named a Top Doctor by Castle Connolly
2015	Named a Top Doctor by Castle Connolly
2019	Inductee, American Society for Clinical Investigation, the nation's oldest honor society of physician-scientists who translate laboratory findings to the advancement of clinical practice.

Regional

2014	Richard T. Jones New Investigator Award. Given to one investigator in Oregon annually for exceptional promise early in a career in biomedical research.
2019	Cancer Prevention Research Institute of Texas Recruitment of Rising Stars Award (declined)

Institutional

1993-1994	University of Texas at Austin, College Scholar
1993-1994	University of Texas at Austin, Dean's List
2004	Named Bernard Schwartz Scholar in Prostate Cancer Research at Johns Hopkins University
2008	Named Robert Gerding Scholar in Prostate Cancer Research at Oregon Health & Science University
2009	OCTRI (Oregon Clinical & Translational Research Institute) Certificate of Achievement for "Best Illustration of Progress Towards Publication," awarded for project entitled "Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating HDAC6"
2013	Inventors of Technologies Award "Identifying androgen-independent prostate cancer"
2017	Named Wayne D. Kuni & Joan E. Kuni Endowed Chair for Prostate Cancer Research
2018	First Place, OHSU Symposium on Educational Excellence Education Research Category

2018	OHSU School of Medicine Paper of the Month: Sehrawat, et al: LSD1 activates a lethal prostate cancer gene network independently of its demethylase function
2018	Outstanding Mentor Award, OHSU School of Medicine Medical Student Capstone Scholarly Program
2019	OHSU Office of Continuing Professional Development Scientific Mentoring and Development Award in recognition of the OHSU School of Medicine Junior Faculty Advancement Program that I co-led
2019	University of Michigan Rogel Cancer Center Rogel Scholar Award

Memberships in Professional Societies

2002-present	Member, American College of Physicians (ACP)
2002-present	Member, American Society of Clinical Oncology (ASCO)
2002-present	Member, American Society of Hematology (ASH)
2003-present	Member, American Association for Cancer Research (AACR)
2007-present	Member, Southwest Oncology Group (SWOG)
2008-present	Member, Radiation Therapy Oncology Group (RTOG)
2012-present	Member, Oregon Society of Medical Oncology (OSMO)
2019-present	Member, American Society for Clinical Investigation (ASCI)

Editorial Positions, Boards, and Peer-Review Service

Study Sections

International

2013	Prostate Cancer Foundation Scientific Review Committee Member
2013	Prostate Cancer Foundation – Challenge Award Grant Review
2013	Prostate Cancer Foundation – New Investigator Award Grant Review
2013	Prostate Cancer Foundation – New Investigator Award Grant Review
2013	Prostate Cancer Foundation/Movember– Challenge Award for Immunotherapy Grant Review
2014	Prostate Cancer Foundation- Challenge Award Grant Review
2015	Prostate Cancer Foundation – Challenge Award Grant Review
2015	Prostate Cancer UK – Translational Research Grants
2016	Prostate Cancer Foundation – Challenge Award Grant Review
2016	Prostate Cancer Foundation – New Investigator Award Grant Review
2017	Prostate Cancer Foundation – Challenge Award Grant Review
2018	Prostate Cancer Foundation – Challenge Award Grant Review
2018	Prostate Cancer Foundation – New Investigator Award Grant Review
2019	Breast Cancer Now Foundation (Ad Hoc)
2019	Prostate Cancer Foundation – Challenge Award Grant Review
2019	Prostate Cancer Foundation – New Investigator Award Grant Review

National

2013	Developmental Therapeutics (DT) Study Section NIH (Ad Hoc)
2014	VA Merit Review Subcommittee for CLNB (Ad Hoc)
2017	Basic Mechanisms of Cancer Therapeutics (BMCT) Study Section NIH (Ad Hoc)
2019	Developmental Therapeutics (DT) Study Section NIH (Ad Hoc)

Regional

2009	Pacific NW Prostate Cancer SPORE Pilot Grant Review Study Section
------	---

2010	Pacific NW Prostate Cancer SPORE Pilot Grant Review Study Section
2015	Pacific NW Prostate Cancer SPORE Pilot Grant Review Study Section
2018	OHSU Knight Cancer Institute Translational Oncology Program Pilot Grant Review
2019	Pacific NW Prostate Cancer SPORE Pilot Grant Review Study Section
2020	Michigan Prostate SPORE Pilot Grant Review Study Section
2021	Michigan Prostate SPORE Pilot Grant Review Study Section
2021	Rogel Cancer Center Translational Grant Study Section

Institutional

2012	Oregon Clinical and Translational Research Institute (OCTRI) Catalyst Grant Review
2012	Oregon Clinical and Translational Research Institute (OCTRI) OSLER TL1/AHRQ T32 Grant Review
2013	OHSU Knight Cancer Institute – Knight Pilot Award Grant Review
2013	Oregon Clinical and Translational Research Institute (OCTRI) OSLER TL1/AHRQ T32 Grant Review
2014	Circle of Giving OHSU Center for Women's Health Grant Review
2015	Oregon Clinical and Translational Research Institute (OCTRI) Catalyst Grant Review
2016	Circle of Giving OHSU Center for Women's Health Grant Review
2017	OHSU Center for Early Detection Pilot Project Review
2017	OHSU Knight Cancer Institute Pilot Project Review
2017	OHSU Knight Cancer Institute Translational Oncology Program Pilot Grant Review
2018	OHSU Knight Cancer Institute Translational Oncology Program Pilot Grant Review
2018	OHSU Knight Cancer Institute Umpqua Bank Innovation Award Grant Review

Editorial Boards

2017-present	Member, Clinical Oncology News
--------------	--------------------------------

Journal Reviewer

2009-present	Blood
2009-present	International Journal of Experimental Pathology
2009-present	Journal of Urology
2010-2012	Associate Scientific Advisor, Science Translational Medicine, Journal of Science Magazine and the AAAS
2011-present	Clinical Cancer Research
2013-present	PLOS One
2014-present	Cancer Research
2015-present	JAMA Oncology
2015-present	Oncotarget
2018-present	Journal of Clinical Investigation
2018-present	Journal of Clinical Oncology
2020-present	British Journal of Cancer
2020-present	European Urology
2020-present	Genome Medicine
2020-present	JCI Insight
2021-present	Proceedings of the National Academy of Sciences

Teaching

Advanced Post Graduate Fellow

08/2017-06/2019	Daehwan Kim, Ph.D., Oregon Health & Science University
-----------------	--

08/2019-present Joel Yates, Ph.D., University of Michigan

Faculty Member

06/2008 Ilya Tsimafeyeu, MD, Kidney Cancer Research Bureau, Moscow, Russia
06/2016-06/2017 Ilya Tsimafeyeu, MD, Prostate Cancer Foundation Coffey-Holden Academy research retreat
08/2016-08/2017 Sophia Bornstein, MD/Ph.D., Oregon Health & Science University
03/2018-present Zachery Reichert, MD/Ph.D., University of Michigan
08/2018-06/2019 Rajan Kulkarni, MD, Oregon Health & Science University
10/2020-present Philip Palmboos, MD, Ph.D., University of Michigan
08/2021-present Abhijit Parolia, Ph.D., University of Michigan

Medical Student

08/2009 Luai Zarour, MD, Oregon Health & Science University
08/2011 Sophia Bornstein, MD/Ph.D., Oregon Health & Science University
08/2012 Mindy Myzak, MD/Ph.D., Oregon Health & Science University
08/2012 Mario Padilla, MD, Oregon Health & Science University
08/2012 Mizuho Mimoto, MD/PhD, Oregon Health & Science University
08/2013-04/2016 Kristen Stevens, MD/Ph.D., Oregon Health & Science University
08/2014 Neil Mistry, MD, Oregon Health & Science University
08/2014-08/2015 Joshua Woodward, MD, Oregon Health & Science University
08/2016-08/2017 Derrick Tao, MD, Oregon Health & Science University
08/2017-12/2017 Sunil Joshi, MD/PhD, Oregon Health & Science University
08/2018-12/2018 Brennan Olson, MD/Ph.D, Oregon Health & Science University
01/2019-06/2019 Claire Turina, MD, Oregon Health & Science University

Postdoctoral Fellow

08/2007-06/2008 Vivianne Deng, Ph.D., Oregon Health & Science University
08/2009-06/2016 Lina Gao, Ph.D., Oregon Health & Science University
08/2011-04/2012 Christine Barnett, MD, Oregon Health & Science University
08/2011-04/2012 Richard Kleinschmidt, Ph.D., Oregon Health & Science University
08/2013-04/2014 Kathryn Van Hook, Ph.D., Oregon Health & Science University
08/2014-06/2019 Daniel Coleman, Ph.D., Oregon Health & Science University
08/2015-06/2019 Archana Sehrawat, Ph.D., Oregon Health & Science University
08/2016-08/2017 Junior Tayou, Ph.D., Oregon Health & Science University
08/2018-06/2019 Chelsea Jenkins, Ph.D., Oregon Health & Science University
08/2018-06/2019 Ece Eksi, Ph.D., Oregon Health & Science University
10/2019-10/2020 Katy Welker Leng, Ph.D., University of Michigan
01/2020-present Anbarasu Kumaraswamy, Ph.D., University of Michigan
11/2020-present William Storck, Ph.D., University of Michigan

Resident/House Officer

08/2016-07/2019 Eric Lu, MD, Oregon Health & Science University
07/2021-present Thomas Westbrook, MD, University of Michigan
07/2021-present Allison May, MD, University of Michigan

Undergraduate Student

08/2007-06/2008 Alex Perepechev, High School Diploma, OHSU CURE Program
08/2010 Josh Buehler, MD, Oregon Health & Science University

08/2011 Neela Ramanujam, MD, Oregon Health & Science University
 08/2015 Natalie Lerner, BS, Oregon Health & Science University
 08/2018-12/2018 Edward Nguyen, BS, Lewis & Clark University

Teaching Activity

Institutional

05/2009 CELL616 Advanced Topics in Cancer Biology: Prostate cancer pathology and treatment" upper level graduate program course in cancer biology

10/2009 HIP514 Molecular & Cellular Approaches to Disease: "Epigenetics," upper level graduate program course in clinical research and molecular biology

06/2010 OSLER TL1, "Go Your Own Way," course in clinical and translational research for pre-doctoral medical and dental students

10/2010 HIP514 Molecular & Cellular Approaches to Disease: "Epigenetics," upper level graduate program course in clinical research and molecular biology

05/2011 CELL616 Advanced Topics in Cancer Biology: "Prostate Cancer 101," upper level graduate program course in cancer biology

10/2011 HIP514 Molecular & Cellular Approaches to Disease: "Epigenetics," upper level graduate program course in clinical research and molecular biology

05/2012 CELL616 Advanced Topics in Cancer Biology: "Advance Topics in Cancer (Clinical Aspects of Prostate Cancer)" upper level graduate program course in cancer biology

11/2012 HIP514 Molecular & Cellular Approaches to Disease: "Epigenetics," upper level graduate program course in clinical research and molecular biology

05/2013 CELL616 Advanced Topics in Cancer Biology: "Advance Topics in Cancer (Prostate Cancer)" upper level graduate program course in cancer biology

11/2013 HIP514 Molecular & Cellular Approaches to Disease: "Targeting Mechanisms of Castration-Resistance in Prostate Cancer" upper level graduate program course in clinical research and molecular biology

05/2014 CELL616 Advanced Topics in Cancer Biology: "Prostate Cancer 101" upper level graduate program course in cancer biology

11/2014 HIP514 Molecular & Cellular Approaches to Disease: "Mechanisms of Treatment Resistance" upper level graduate program course in clinical research and molecular biology

05/2015 CELL616 Advanced Topics in Cancer Biology: "Prostate Cancer 101" upper level graduate program course in cancer biology

11/2015 HIP514 Molecular & Cellular Approaches to Disease: "Mechanisms of Treatment Resistance" upper level graduate program course in clinical research and molecular biology

05/2016 CELL616 Advanced Topics in Cancer Biology: "Prostate Cancer" upper level graduate program course in cancer biology

01/2017-05/2017 CELL616 Advanced Topics in Cancer Biology Course Co-Director:(upper level graduate program course in cancer biology)

04/2017 CELL616 Advanced Topics in Cancer Biology: "Prostate Cancer 101" upper level graduate program course in cancer biology

11/2017 HIP514 Molecular & Cellular Approaches to Disease: "Mechanisms of Treatment Resistance" upper level graduate program course in clinical research and molecular biology

05/2018 CELL616 Advanced Topics in Cancer Biology: "Prostate Cancer 101" upper level graduate program course in cancer biology

10/2018 HIP514 Molecular & Cellular Approaches to Disease: "Cracking the Code of Advanced Prostate Cancer" upper level graduate program course in clinical research and molecular biology

05/2019 CELL616 Advanced Topics in Cancer Biology: "Prostate Cancer 101" upper level graduate program course in cancer biology

09/2019	Cancer Biology Research Seminar: "Targeting Lethal Prostate Cancer Transcriptional Networks" upper level graduate program in cancer biology
04/2021	Cancer Biology 554: "Prostate Cancer 101" lecture

Dissertation Committees

2009	Trevor Levin, I served on his thesis committee. Dr. Levin's research characterized the intestinal cancer stem marker CD166 in the human and mouse gastrointestinal tract., Oregon Health and Science University, Cancer Cell Development, Committee Member
2014	Ellie Juarez, Worked on "Investigation of the SWI/SNF Chromatin Remodeling Complex in the Repair of DNA-Protein Cross Links." Dr. Juarez is now a post-doctoral fellow at OHSU., Oregon Health and Science University, Cancer Cell Development, Committee Member
2014	Marilynn Chow, She worked on "Delineation of ROR1 Signaling and its Genetic Regulation to Define New Therapeutic Modalities for t(1;19) B-ALL Patients." Dr. Chow is now a post-doctoral fellow at OHSU., Oregon Health and Science University, Cancer Cell Development, Committee Member
2014	Tyler Risom, He worked on "Overcoming lineage plasticity and phenotypic resistance in basal-like breast cancer with combination therapy." Dr. Risom is now a post-doctoral fellow at Stanford., Oregon Health and Science University, Cancer Cell Development, Committee Member
2018	Ryan Mulqueen, I served on his qualifying exam, Oregon Health and Science University, Cancer Center Development, Committee Member
2020	Estefania Martinez Valdivia, I served on her qualifying exam, University of Michigan, Internal Medicine, Committee Member
2021	Alan Kelleher, Cancer Biology Graduate Program, University of Michigan, Internal Medicine, Committee Member

Committee and Administrative Services

Committee Services

International

2011	National Cancer Institute Provocative Questions Workshop, Member
2015-2019	Via Pathways Prostate Medical Oncology Committee, Member
2017	Signaling Pathways II Session Moderator, 10th Annual Multi-Institutional Prostate Cancer SPORE Retreat, Member
2018	National Cancer Institute Committee on Lineage Plasticity and AR-Independent Prostate Cancer, Member
2019-present	ASCO Scientific Program Committee, Member
2020-present	NCI Cancer Moonshot Drug Resistance and Sensitivity Network, Member

National

2011-2013	American Cancer Society Oregon Chapter, Board Member
-----------	--

Institutional

2008-2015	Fellowship Admissions Committee, Division of Hematology and Medical Oncology
2011-2014	Clinical Research Review Committee (CRRC), Member
2011	2011 Student Research Forum, Judge for Biochemistry section
2011	OHSU Knight Cancer Institute Technology Development Manager, Member of Search Committee
2012-2014	Hematology/Oncology Division Head Search Committee, Member
2012-2014	Knight Clinical Research Resource Allocation Committee, Member
2012-2019	Division of Urology Basic Scientist Search Committee, Member
2013-2019	School of Medicine Dean's Research Committee, Member
2014-2015	Cell & Developmental Biology Assistant Professor Search Committee, Member

2014-2019	Research Mentoring Committee, Division of Hematology and Medical Oncology, Member
2015-2019	Cell, Developmental & Cancer Biology/Knight Cancer Institute Junior Faculty Advancement Program, Member
2015-2019	Fellowship Education Committee, Division of Hematology/Oncology, Member
2015-2019	Knight Cancer Institute Drug Discovery Steering Committee, Member
2016-2017	Knight Cancer Institute Junior Faculty Advancement Committee, Co-Director
2016-2017	OHSU Knight Cancer Institute Strategic Space Planning Committee to organize the entire Knight Cancer Institute research footprint on campus, including two new buildings, Member
2016	Department of Pediatrics Review Committee, Member
2016	OHSU Translational Research Hub Committee, Member
2016	Promotion Evaluation Committee - Brooke Beckett, Member
2017-2019	OHSU Knight Cancer Institute Strategic Vision Committee, Member
2017-2019	OHSU School of Medicine Junior Faculty Advancement Program, Co-Director
2017-2019	Prostate Cancer Arm of OHSU Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Precision Medicine Trial, Principal Investigator
2017-2019	Prostate Cancer Research Program Faculty Recruit Search Committee, Head
2017	Promotion Evaluation Committee - Emek Demir, Member
2017	Promotion Evaluation Committee - Kim-Hien Dao, Member
2018-2019	Internal Advisory Board for the Oregon Clinical and Translational Research Institute (OCTRI)-OHSU's NIH-funded Clinical Translational Science Award, Chair
2019-present	University of Michigan Division of Hematology-Oncology Fellowship Review Committee, Member
2019	Internal Advisory Board for Knight Cancer Institute Cancer Biostatistics Shared Resource, Member
2019	Oregon Health & Science University School of Medicine Clinical Scientist Task Force, Member
2020-present	Rogel Cancer Center Clinical Intake Working Group, Member
2021-present	University of Michigan Rogel Cancer Center Cancer Data Sciences Shared Resources Advisory Board, Member
2021	University of Michigan Gastroenterology Division Chief Search Committee, Member

Administrative Services

Volunteer

2014-2019	Co-Director, Prostate Cancer SPORE, NIH Pacific Northwest, Translational Science Seminar Series
2017-2019	Member, Cancer Early Detection Advanced Research (CEDAR), OHSU, Prostate Cancer Working Group

Visiting Professorships and Extramural Invited Presentations

Extramural Invited Presentations

1. *Elucidation of Clinically Significant Mechanism of Gene Silencing*, CROET Seminar Series, March 2007, Portland, OR
2. *Prostate Cancer Laboratory Research: How It Advances Care*, Portland Pearl Rotary Club, June 2007, Portland, OR
3. *Early Prostate Cancer: An Overview of Treatment and Clinical and Molecular Predictors of Outcome*, Dept. of Medicine Grand Rounds, June 2007, Portland, OR
4. *Prostate Cancer Update*, ASCO Updates in Oncology, June 2007, Portland, OR
5. *Towards a better understanding of prostate cancer*, Rotary Club of East Portland, July 2007, Portland, OR
6. *Translational Laboratory Research: How It Advances Care*, 7th Annual Pacific NW Prostate Cancer Conference, September 2007, Portland, OR

7. *Towards a Greater Understanding of Prostate Cancer Development and Progression*, Portland Rotary Club, January 2008, Portland, OR
8. *Identifying and Targeting Aggressive Prostate Cancer*, Advancements in Prostate Cancer Research and Care Luncheon, February 2008, Portland, OR
9. *Characterization of new mechanisms of sulforaphane action in prostate cancer*, PNW Prostate Cancer SPORE Scientific Symposium, February 2008, Seattle, WA
10. *Translational Research in Prostate Cancer*, American Cancer Society, June 2008, Portland, OR
11. *Advances in Prostate Cancer*, ASCO Updates in Oncology Conference, June 2008, Portland, OR
12. *Epigenetics and Prostate Cancer*, PPCR/SPORE, July 2008, Seattle, WA
13. *Advances in Prostate Cancer*, ASCO Updates in Oncology Conference, June 2009, Portland, OR
14. *Research training: Or how to become who you may become.*, OCTRI (Oregon Clinical Translational Research Institute) Summer Medical Student Forum, June 2009, Portland, OR
15. *Towards a Better Understanding of Prostate Cancer*, Providence Milwaukie Prostate Cancer Support Group, July 2009, Portland, OR
16. *Towards a Better Understanding of Prostate Cancer*, Portland Rotary Club, July 2009, Portland, OR
17. Elucidation of Novel Mechanisms of Sulforaphane Chemoprevention in a Murine Model, PPCR/SPORE Speaker Seminar, August 2009, Seattle, WA
18. Translational Laboratory Research: How it Advances Care., 9th Annual Pacific NW Prostate Cancer Conference, September 2009, Portland, OR
19. Prostate Cancer Hormonal Therapy 101, Lecture to Radiation Oncology residents, September 2009, Portland, OR
20. IMER, Grand Rounds, September 2009, Kennewick, WA
21. Sulforaphane and Prostate Cancer, National Cancer Institute (NCI) Translational Science Meeting, November 2009, Vienna, VA
22. LSD1 and Prostate Cancer, Pacific NW Prostate Cancer SPORE Retreat, November 2009, Vancouver, BC
23. Sulforaphane Chemoprevention in a Murine Model: Novel Mechanisms, Pacific NW Prostate Cancer SPORE Meeting, November 2009, Seattle, WA
24. Translational Laboratory Research: How it Advances Care, Sharp Microelectronics of the Americas for the American Association for Cancer Research education week, November 2009, Camas, WA
25. Clinical Debates in Castration-Refractory Prostate Cancer, IMER Grand Rounds, June 2010, Roseburg, OR
26. Prostate Cancer Update, ASCO Updates in Oncology, July 2010, Portland, OR
27. *A microarray-based study of DNA methylation changes in prostate cancer*, Pacific NW Prostate Cancer SPORE Retreat, July 2010, Seattle, WA
28. Sulforaphane and Prostate Cancer: From Bench to Bedside, Johns Hopkins University, September 2010, Baltimore, MD
29. Translational Laboratory Research: How it Advances Care, 10th Annual Pacific NW Prostate Cancer Conference, October 2010, Portland, OR
30. Prostate Cancer, Betty Hise Trust for Cancer Research Annual Meeting, April 2011, Salem, OR
31. Thinking Outside the (Androgen) Box in Prostate Cancer, Molecular and Medical Genetics Grand Rounds, May 2011, Portland, OR
32. Overcoming Prostate Cancer, Kuni Foundation Spring meeting, May 2011, Portland, OR
33. Understand and Overcoming Prostate Cancer, Collins Medical Trust Presentation, May 2011, Portland, OR
34. Prostate Cancer Update, ASCO Updates in Oncology, June 2011, Portland, OR
35. Prostate Cancer Treatment, Hematology/Oncology Grand Rounds, August 2011, Portland, OR
36. Translational Laboratory Research: How it Advances Care, 11th Annual Pacific NW Prostate Cancer Conference, October 2011, Portland, OR
37. Thinking Outside the (Androgen) Box in Prostate Cancer, University of Texas Health Science Center Oncology Ground Rounds, November 2011, Houston, TX

38. Genitourinary Cancer (Prostate), Session Chair, ASCO, November 2011, Chicago, IL
39. Thinking Outside the (Androgen) Box in Prostate Cancer, Knight Cancer Institute Biology Research Group, January 2012, Portland, OR
40. Advances in Prostate Cancer Treatment: Lessons Learned, MD/PhD Journal Club, February 2012, Portland, OR
41. Cancer 101, 2012 NACCDO/PAN Annual Conference, May 2012, Portland, OR
42. Early and More Complete Androgen Blockade in Prostate Cancer, Clinical Science Symposium Discussant, ASCO Annual Meeting, June 2012, Chicago, IL
43. Prostate Cancer Update, ASCO Updates in Oncology, June 2012, Portland, OR
44. "The Emperor of All Maladies: A Biography of Cancer" by Siddhartha Mukherjee, Medical Students Book Club, August 2012, Portland, OR
45. How to manage PSA recurrence, 12th Annual Pacific NW Prostate Cancer Conference, October 2012, Portland, OR
46. Identifying the LSD1 network in prostate cancer, PPCR/SPORE Discussion Meeting, January 2013, Portland, OR
47. Targeting the Androgen Receptor in Castration-Resistant Prostate Cancer, Portland City-wide Oncology Journal Club, February 2013, Portland, OR
48. Prostate Cancer Update, ASCO Updates in Oncology, June 2013, Portland, OR
49. Emergent signaling pathways in enzalutamide-resistant prostate cancer, Pacific NW Prostate Cancer SPORE Retreat, July 2013, Seattle, WA
50. Translational Laboratory Research: How it advances care, 13th Annual Pacific NW Prostate Cancer Conference, September 2013, Portland, OR
51. Enzalutamide Resistance Mechanisms in Prostate Cancer, SPORE Lecture/Risk Prevention/Outcomes Talk, April 2014, Portland, OR
52. Targeting Emergent Enzalutamide Resistance Mechanisms, Session: New SU2C Dream Teams: Patient Benefit Through Targeted Therapeutics and Immunotherapy, Annual AACR Annual Meeting, April 2014, San Diego, CA
53. Vision to Cure Cancer, Arlington Club Luncheon/Talk, May 2014, Portland, OR
54. Identifying enzalutamide resistance mechanisms in men with castration-resistant prostate cancer, ASCO Annual Meeting, May 2014, Chicago, IL
55. Prostate Cancer Update, ASCO Updates in Oncology, June 2014, Portland, OR
56. Who's on First? PREVAIL and CHARTED in metastatic prostate cancer, City-wide Journal Club, July 2014, Portland, OR
57. How to manage PSA recurrence, 14th Annual Pacific NW Prostate Cancer Conference, September 2014, Portland, OR
58. Integrative Genomic Analysis to Identify Emergent Enzalutamide Resistance Mechanisms in Castration-Resistant Prostate Cancer, 21st Annual Prostate Cancer Foundation Scientific Retreat, October 2014, Carlsbad, CA
59. The effects of sulforaphane treatment in men with biochemical recurrence of prostate cancer, SPORE Lecture/Risk Prevention/Outcomes Talk, November 2014, Portland, OR
60. Integrative Genomic Analysis to Identify Emergent Enzalutamide Resistance in Castration-Resistant Prostate Cancer, American Association of Cancer Research Annual Meeting, April 2015, Philadelphia, PA
61. Androgens Interfere with Enzalutamide Agonism of Mutant F876L Androgen Receptor, American Association of Cancer Research Annual Meeting, April 2015, Philadelphia, PA
62. Targeting Emergent Resistance Mechanisms in Advanced Prostate Cancer, VICC/C2T2 ViP Seminar Series Visiting Speaker, June 2015, Nashville, TN
63. The role of histone demethylation in LSD1-induced gene activation, Pacific NW Prostate Cancer Discussion Meeting, June 2015, Portland, OR
64. Prostate Cancer Highlights from ASCO 2015, ASCO Updates in Oncology, June 2015, Portland, OR
65. Targeting LSD1 in Prostate Cancer, SPORE/EAB Meeting, July 2015, Stevenson, WA
66. Integrative Genomic Analysis to Identify Emergent Enzalutamide Resistance Mechanisms in Castration-Resistant Prostate Cancer, 6th PacRim Breast and Prostate Cancer Meeting, July 2015, Stevenson, WA

67. Translational Laboratory Research: How it advances care, 15th Annual Pacific NW Prostate Cancer Conference, September 2015, Portland, OR
68. LSD1 Inhibition for Treatment of Prostate Cancers, Huntsman Cancer Institute Experimental Therapeutics Program Retreat Visiting Speaker, November 2015, Salt Lake City, UT
69. Targeting Emergent Mechanisms of Castration-Resistance in Prostate Cancer, Knight Cancer Research Group Meeting, December 2015, Portland, OR
70. Targeting Emergent Castration-Resistance Mechanisms in Prostate Cancer, Hematology/Oncology Research Conference, February 2016, Portland, OR
71. New and Better Treatment for Advanced Prostate Cancer, Columbia Memorial – Grand Rounds, May 2016, Astoria, OR
72. CRPC Resistance and BETi, Zenith Investigator Meeting, June 2016, Chicago, IL
73. Prostate Cancer, ASCO Updates in Oncology Conference, July 2016, Portland, OR
74. Project 2: Targeting LSD1 in Prostate Cancer, Pacific Northwest Prostate Cancer SPORE Advisory Board Meeting, July 2016, Seattle, WA
75. Pre/Post Therapy Paired Biopsies, Stand Up 2 Cancer Dream Team Review, July 2016, Chicago, IL
76. Distinct CRPC Subtypes/Heterogeneity Genzyme, Prostate Cancer Preceptorship, August 2016, Portland, OR
77. Immunotherapy Landscape in Prostate Cancer, Xofigo Medical Science Liaison Training Symposium, August 2016, Portland, OR
78. AR Action in Prostate Cancer and New Approaches to Target It, Genzyme Prostate Cancer Preceptorship, August 2016, Portland, OR
79. Prostate Cancer Overview and Cases, Xofigo Medical Science Liaison Training Symposium, August 2016, Portland, OR
80. Treatment Landscape for Metastatic Castration– Resistant Prostate Cancer, Xofigo Medical Science Liaison Training Symposium, August 2016, Portland, OR
81. Targeting Emergent Resistance Mechanisms in Advanced Prostate Cancer, University of Michigan Cancer Center Guest Lecture Series, August 2016, Ann Arbor, MI
82. AR Action in Prostate Cancer and New Approaches to Target It, Genzyme Prostate Cancer Preceptorship, September 2016, Portland, OR
83. Distinct CRPC Subtypes/Heterogeneity Genzyme, Prostate Cancer Preceptorship, September 2016, Portland, OR
84. Prostate cancer progress and personalized therapy, Marquam Hill Steering Committee, October 2016, Portland, OR
85. Targeting AR-Independent Mechanisms of Prostate Cancer Progression with BET Bromodomain Inhibition, Pacific NW Prostate Cancer Discussion Meeting, November 2016, Portland, OR
86. AR null phenotype and BETi, Zenith Investigator Meeting at ASCO, ASCO, June 2017, Chicago, IL
87. Prostate Cancer Update, ASCO Updates in Oncology Conference, June 2017, Portland, OR
88. Identification of acquired enzalutamide resistance mechanisms in men with advanced prostate cancer, University of California San Francisco Prostate Cancer Research Program, August 2017, San Francisco, CA
89. Targeting Emergent Enzalutamide Resistance Mechanisms in Advanced Prostate Cancer, SPORE Patient Advocacy Committee, August 2017, Portland, OR
90. Management of Advanced Prostate Cancer and Novel Agents on the Horizon, 17th Annual Pacific NW Prostate Cancer Conference, September 2017, Portland, OR
91. Targeting Lethal Prostate Cancer Transcriptional Networks, Vancouver Prostate Centre Grand Rounds, November 2017, Vancouver, British Columbia, Canada
92. Targeting Lethal Prostate Cancer Transcriptional Networks, Emory University Winship Cancer Center Visiting Professor Series, December 2017, Atlanta, GA
93. PARADIGM Genomic Analysis, Prostate Cancer Foundation Journal Club, May 2018, Chicago, IL
94. Enzalutamide in non-metastatic CRPC: Results from PROSPER, Genitourinary Malignancies Expert Forum, May 2018, Dallas, TX
95. Approaches to block persistent AR function in metastatic CRPC resistant to novel AR targeting agent, Genitourinary Malignancies Expert Forum, May 2018, Dallas, TX

96. AR Independent Mechanisms of BET Bromodomain Inhibition in Prostate Cancer, Zenith Epigenetics Investigators' Meeting, June 2018, Chicago, IL
97. Targeting Lethal Prostate Cancer Transcriptional Networks, UT Southwestern Medical Center Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research Invited Speaker Series, June 2018, Dallas, TX
98. Translational Laboratory Research: How it advances care, 18th Annual Pacific NW Prostate Cancer Conference, September 2018, Portland, OR
99. Targeting Lethal Prostate Cancer Transcriptional Networks,, Fred Hutchinson Cancer Research Center NIH Pacific Northwest Prostate Cancer SPORE Translational Research Seminar Series,, October 2018, Seattle, WA
100. Targeting Lethal Prostate Cancer Transcriptional Networks, Oregon Translational Chemical Biology Symposium, October 2018, Portland, OR
101. An Integrative Approach to Studying Lethal Human Prostate Cancer, University of Michigan Division of Hematology-Oncology Research Conference, December 2018, Ann Arbor, MI
102. Evolving Treatment Landscape in Prostate Cancer: A Patient-Centric Perspective, Astellas Oncology Forum II, October 2019, Sao Paulo, Brazil
103. An Integrative Approach to Studying Lethal Human Prostate Cancer, Michigan Prostate SPORE Research Conference, October 2019, Ann Arbor, MI
104. Transcriptional Profiling Identifies an Androgen Receptor Activity-Low, Stemness Program Associated with Enzalutamide Resistance, Multi-Institutional Prostate Cancer SPORE Retreat, March 2020, Fort Lauderdale, FL
105. *Targeting Lethal Prostate Cancer Transcriptional Networks*, Prostate Cancer Foundation Coffey-Holden Meeting, May 2020, Cancelled Due to COVID-19
106. Transcriptional Profiling Identifies an Androgen Receptor Activity-Low, Stemness Program Associated with Enzalutamide Resistance, Multi-Institutional Prostate Cancer SPORE Monthly Conference, May 2020, Zoom
107. Alternate Splicing of LSD1+8a in Neuroendocrine Prostate Cancer is Medicated by SRRM4, Prostate Cancer Foundation Tumorigenesis Journal Club, June 2020, Zoom
108. Clarifying the Role of LSD1 in Neuroendocrine Prostate Cancer, NCI Drug Resistance and Sensitivity Network Seminar Series, November 2020, Virtual
109. Targeted Oncology Prostate Cancer Case-Based Peer Perspectives with Dr. Joshi Alumkal, Virtual Case-Based Roundtable Event, December 2020, Virtual
110. Cracking the Code of Lethal Prostate Cancer, OHSU: Brown Bag Series, December 2020, Virtual Meeting
111. Human Subjects Research and IRBs, PIBS- Program in the Biomedical Sciences, January 2021, Virtual
112. Escalating Androgen Receptor Signaling Inhibition: More May be Better, but For Whom?, 2021 ASCO Genitourinary Cancers Symposium, February 2021, Virtual
113. Targeted Oncology Case-Based Roundtable with Dr. Joshi Alumkal and Dr. Yousef Zakharia, Targeted Oncology Case-Based Roundtable Meeting, March 2021, Virtual
114. Targeting Critical Epigenetic Factors that Promote Prostate Cancer Lineage Plasticity, Prostate Cancer Foundation/Coffey-Holden Meeting, June 2021, Virtual

Seminars

1. *Identification of the Prostate Cancer Hypermethylome*, OHSU GMSR Microarray Users Forum, January 2009, Portland, OR
2. Thinking Outside the (Androgen) Box in Prostate Cancer, Oregon Health & Science University Molecular and Medical Genetics Seminar, May 2010, Portland, OR
3. Assays for epigenetic control points, Oregon Health & Science University Hematologic Malignancies Retreat, May 2010, Newberg, OR
4. Thinking Outside the (Androgen) Box in Prostate Cancer, Oregon Health & Science University MD/PhD Grand Rounds Presentation, August 2010, Portland, OR
5. Thinking Outside the (Androgen) Box in Prostate Cancer,, Oregon Health & Science University Department of Biomedical Engineering (BME) Seminar Series, December 2010, Portland, OR
6. Sulforaphane Treatment in Men With Recurrent Prostate Cancer, OHSU Research Week, May 2013, Portland, OR

7. Identifying and Targeting Enzalutamide Resistance Mechanisms in Prostate Cancer, OHSU Knight Cancer Institute Scientific Retreat, October 2013, Welches, OR
8. Targeting LSD1 in Prostate Cancer, Biomedical Engineering/OHSU Center for Spatial Systems Biomedicine (BME/OCSSB) Grand Rounds, January 2014, Portland, OR
9. Targeting Mechanisms of Treatment Resistance in Prostate Cancer, OHSU Knight Cancer Institute, Hem/Onc Fellows Weekly Case Conference, January 2014, Portland, OR
10. Targeting Mechanisms of Treatment Resistance in Prostate Cancer, OHSU Knight Cancer Institute Research Group Meeting, January 2014, Portland, OR
11. Prostate Cancer Overview, OHSU Nursing Education Lecture, August 2014, Portland, OR
12. Integrative genomic analysis to identify emergent resistance mechanisms in prostate cancer, OHSU Knight Cancer Institute Solid Tumors & Quantitative Oncology Programs' Joint Retreat, November 2014, Portland, OR
13. IM Subspecialties Panel for first-year medical students, OHSU, January 2015, Portland, OR
14. Making Cancer History, OHSU Foundation Community Talk in the Desert Event, March 2015, Palm Springs, CA
15. Androgen signaling, treatment resistance affects, Adenocarcinoma vs. neuroendocrine prostate cancer, AR-V7, future treatment decisions, chemo resistance, Primary and Acquired resistance. Questions: PSA and how it affects treatment decision making, OHSU/Sanofi Preceptorship, August 2015, Portland, OR
16. Androgen signaling, treatment resistance affects, Adenocarcinoma vs. neuroendocrine prostate cancer, AR-V7, future treatment decisions, chemo resistance, Primary and Acquired resistance. Questions: PSA and how it affects treatment decision making, OHSU/Sanofi Preceptorship, September 2015, Portland, OR
17. Managing Advanced Prostate Cancer, OHSU Radiation Oncology Resident Didactics Lecture Series, October 2016, Portland, OR
18. An academic life, OHSU Hem-Onc Fellows' Retreat, November 2016, Newberg, OR
19. Clarifying Mechanisms of BET Bromodomain Inhibitor (BETi) Response and Resistance in Lethal Prostate Cancer, OHSU Knight Translational Oncology and Cancer Biology Program, January 2017, Portland, OR
20. An academic life, OHSU Physician-Scientist Seminar Series, February 2017, Portland, OR
21. Prostate Cancer 101, OHSU Cell 616 Adv Topics in Cancer Biology, April 2017, Portland, OR
22. Epigenetics and Cancer, OHSU Hematology & Medical Oncology Fellowship Conference, May 2017, Portland, OR
23. Targeting Lethal Prostate Cancer Transcriptional Networks, Molecular & Medical Genetics Grand Rounds, November 2017, Portland, OR
24. Understanding resistance to the drug enzalutamide in patients with advanced prostate cancer, OHSU Knight Prostate Cancer Support Group, November 2017, Portland, OR
25. Cracking the Code of Advanced Prostate Cancer, OHSU Marquam Hill Lecture Series for the public, May 2018, Portland, OR
26. Translational Concepts in Lethal Prostate Cancer, OHSU Heme-Onc Fellowship Research Conference, November 2018, Portland, OR
27. Combination Strategies with AR Inhibition in Prostate Cancer, OHSU Knight Cancer Institute SMMART Program Research Conference, December 2018, Portland, OR
28. Targeting Lethal Prostate Cancer Transcriptional Networks, University of Michigan Cancer Biology Research Meeting, September 2019, Ann Arbor, MI
29. An Integrative Approach to Studying Lethal Human Prostate Cancer, University of Michigan Heme-Onc Division Kemp Cease Research Conference, October 2019, Ann Arbor, MI
30. Targeting Lethal Prostate Cancer Transcriptional Networks, University of Michigan Rogel Cancer Center Developmental Therapeutics Program Seminar Series, November 2020, Virtual
31. Recognizing and Seizing the Opportunity to Defeat Advanced Prostate Cancer, University of Michigan Up Cancer Seminar Series, November 2020, Virtual
32. Targeting the Program of Lethal Prostate Cancer, The Rogel Cancer Center Basic Science Retreat, December 2020, Virtual
33. An Integrative Approach to Studying Lethal Human Prostate Cancer, University of Michigan Heme-Onc Division Kemp Cease Research Conference, February 2021, Ann Arbor

34. Targeting Critical Factors that Promote Neuroendocrine Prostate Cancer Lineage Plasticity, Cancer Biology/Cancer Genetics Monthly Program Meeting/ University of Michigan, May 2021, Virtual

Bibliography

Peer-Reviewed Journals and Publications

1. **Alumkal J**, Rice L, Vempathy H, McCarthy JJ, Riggs SA: Surgery-associated factor VIII inhibitors in patients without hemophilia. *Am J Med Sci* 318(5): 350-2, 1999. PM10555100
2. **Alumkal JJ**, Carducci MA: Early use of chemotherapy in conjunction with radical prostatectomy. *Clin Prostate Cancer* 3(3): 144-9, 2004. PM15636680
3. **Alumkal JJ**, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, Partin AW, Garrett-Mayer E, DeMarzo AM, Herman JG: Effect of DNA methylation on identification of aggressive prostate cancer. *Urology* 72(6): 1234-9, 2008. PM18387661/PMC2874954
4. Van Hook K, **Alumkal J**, Lopez CD: hADA2a and hADA3: new players in beta-catenin signaling. *Cancer Biol Ther* 7(1): 129-30, 2008. PM18347424
5. **Alumkal JJ**: Through the looking glass. *Blood* 114(16): 3363-4, 2009. PM19833849
6. Gibbs A, Schwartzman J, Deng V, **Alumkal J**: Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. *Proc Natl Acad Sci U S A* 106(39): 16663-8, 2009. PM19805354/PMC2757849
7. Beer TM, Ryan C, **Alumkal J**, Ryan CW, Sun J, Eilers KM: A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. *Anticancer Drugs* 21(4): 433-8, 2010. PM20016365
8. Dillard T, Yedinak CG, **Alumkal J**, Fleseriu M: Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. *Pituitary* 13(1): 29-38, 2010. PM19639414
9. Zarour L, **Alumkal J**: Emerging therapies in castrate-resistant prostate cancer. *Curr Urol Rep* 11(3): 152-8, 2010. PM20425621/PMC3682789
10. Gao L, **Alumkal J**: Epigenetic regulation of androgen receptor signaling in prostate cancer. *Epigenetics* 5(2): 100-4, 2010. PM20160483/PMC3150559
11. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efsthathiou E, Rathkopf D, Shelkey J, Yu EY, **Alumkal J**, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. *Lancet* 375(9724): 1437-46, 2010. PM20398925/PMC2948179
12. Schwartzman J, Mongoue-Tchokote S, Gibbs A, Gao L, Corless CL, Jin J, Zarour L, Higano C, True LD, Vessella RL, Wilmot B, Bottomly D, McWeeney SK, Bova GS, Partin AW, Mori M, **Alumkal J**: A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. *Epigenetics* 6(10): 1248-56, 2011. PM21946329/PMC3225842
13. Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, **Alumkal JJ**, Thomas G, Thomas GV: A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. *Sci Transl Med* 3(85): 85ra47, 2011. PM21632985/PMC3303496
14. Prins RC, Rademacher BL, Mongoue-Tchokote S, **Alumkal JJ**, Graff JN, Eilers KM, Beer TM: C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. *Urol Oncol* 30(1): 33-7, 2012. PM20207556/PMC2894303
15. **Alumkal JJ**, Herman JG: Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers. *Cancer Discov* 2(11): 979-81, 2012. PM23148372/PMC3661413
16. Weinmann S, Van Den Eeden SK, Haque R, Chen C, Richert-Boe K, Schwartzman J, Gao L, Berry DL, Kallakury BV, **Alumkal JJ**: Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study. *Prostate* 73(13): 1371-7, 2013. PM23661613/PMC3745520
17. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, **Alumkal JJ**, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM: Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. *Ann Oncol* 24(7): 1813-1821, 2013. PM23535954/PMC3707423

18. Ryan CJ, Rosenthal M, Ng S, **Alumkal J**, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR: Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with ritotumumab plus mitoxantrone and prednisone. *Clin Cancer Res* 19(1): 215-24, 2013. PM23136195
19. **Alumkal JJ**, Graff JN, Beer TM: Targeted therapy in prostate cancer: is there hope beyond the androgen receptor? *Oncology (Williston Park)* 27(7): 628, 630, 637-8, 2013. PM23977755
20. Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B, Bottomly D, Coleman I, Nelson P, McWeeney S, **Alumkal J**: Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. *PLoS One* 8(5): e63563, 2013. PM23704919/PMC3660401
21. Van Hook K, Huang T, **Alumkal JJ**: Orteronel for the treatment of prostate cancer. *Future Oncol* 10(5): 803-11, 2014. PM24799061/PMC4148348
22. Hussain M, Carducci MA, Slovin S, Cetnar J, Qian J, McKeegan EM, Refici-Buhr M, Chyla B, Shepherd SP, Giranda VL, **Alumkal JJ**: Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. *Invest New Drugs* 32(5): 904-12, 2014. PM24764124/PMC4659356
23. Goh LK, Liem N, Vijayaraghavan A, Chen G, Lim PL, Tay KJ, Chang M, Low JS, Joshi A, Huang HH, Kalaw E, Tan PH, Hsieh WS, Yong WP, **Alumkal J**, Sim HG: Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer. *PLoS One* 9(3): e91666, 2014. PM24626295 /PMC3953552
24. Hussain M, Corn PG, Michaelson MD, Hammers HJ, **Alumkal JJ**, Ryan CJ, Bruce JY, Moran S, Lee SY, Lin HM, George DJ, Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation.: Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. *Clin Cancer Res* 20(16): 4218-27, 2014. PM24965748
25. **Alumkal JJ**, Slottke R, Schwartzman J, Cherala G, Munar M, Graff JN, Beer TM, Ryan CW, Koop DR, Gibbs A, Gao L, Flamiatos JF, Tucker E, Kleinschmidt R, Mori M: A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. *Invest New Drugs* 33(2): 480-9, 2015. PM25431127/PMC4390425
26. Omlin A, Jones RJ, van der Noll R, Satoh T, Niwakawa M, Smith SA, Graham J, Ong M, Finkelman RD, Schellens JH, Zivi A, Crespo M, Riisnaes R, Nava-Rodrigues D, Malone MD, Dive C, Sloane R, Moore D, **Alumkal JJ**, Dymond A, Dickinson PA, Ranson M, Clack G, de Bono J, Elliott T: AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies. *Invest New Drugs* 33(3): 679-90, 2015. PM25920479
27. Guo M, **Alumkal J**, Drachova T, Gao D, Marina SS, Jen J, Herman JG: CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancer. *Discov Med* 19(104): 151-8, 2015. PM25828518
28. Yu EY, Duan F, Muzi M, Deng X, Chin BB, **Alumkal JJ**, Taplin ME, Taub JM, Herman B, Higano CS, Doot RK, Hartfeil D, Febbo PG, Mankoff DA: Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. *J Nucl Med* 56(3): 354-60, 2015. PM25635138/PMC4410847
29. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, **Alumkal J**, Graff JN, Nordquist LT, Herrera I, Small EJ: Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. *Clin Genitourin Cancer* 13(3): e191-8, 2015. PM25557266
30. Geybels MS, **Alumkal JJ**, Luedeke M, Rinckleb A, Zhao S, Shui IM, Bibikova M, Klotzle B, van den Brandt PA, Ostrander EA, Fan JB, Feng Z, Maier C, Stanford JL: Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors. *Clin Epigenetics* 7: 128, 2015. PM26692910/PMC4676897
31. Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, **Alumkal JJ**, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE: Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. *Eur Urol* 70(6): 963-970, 2016. PM27160947 /PMC5568792
32. **Alumkal JJ**, Beer TM: Raising the Bar for Therapeutic Trials in Advanced Prostate Cancer. *J Clin Oncol* 34(25): 2958-60, 2016. PM27400946

33. Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, **Alumkal JJ**, Huang J, Thomas G, Witte O, Small EJ: Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. *Eur Urol Focus* 2(5): 469-471, 2016. PM28723508
34. Graff JN, **Alumkal JJ**, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM: Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. *Oncotarget* 7(33): 52810-52817, 2016. PM27429197/PMC5288150
35. Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, Heiser LM, **Alumkal JJ**: Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. *Oncotarget* 7(26): 40690-40703, 2016. PM27276681/PMC5130036
36. Quigley D, **Alumkal JJ**, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY: Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of *BRCA2* Reversion Mutations Associated with Resistance to PARP Inhibitors. *Cancer Discov* 7(9): 999-1005, 2017. PM28450426/PMC5581695
37. Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, **Alumkal JJ**, Hauke R, Tutrone RF, Saleh M, Chow Maneval E, Thomas S, Ricci DS, Yu MK, de Boer CJ, Trinh A, Kheoh T, Bandekar R, Scher HI, Antonarakis ES: Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. *Ann Oncol* 28(9): 2264-2271, 2017. PM28633425/PMC5834046
38. Holmes MG, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, **Alumkal JJ**, Beer TM, Small EJ, Link TM: CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. *J Vasc Interv Radiol* 28(8): 1073-1081.e1, 2017. PM28549709
39. Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, **Alumkal JJ**, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME: Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. *J Natl Cancer Inst* 109(12): djx118. doi: 10.1093/jnci/djx118, 2017. PM29206995/PMC6440274
40. **Alumkal JJ**, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS: Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. *Clin Genitourin Cancer* 15(5): 610-617.e3, 2017. PM28344102
41. Winters-Stone KM, Moe E, Graff JN, Dieckmann NF, Stoyles S, Borsch C, **Alumkal JJ**, Amling CL, Beer TM: Falls and Frailty in Prostate Cancer Survivors: Current, Past, and Never Users of Androgen Deprivation Therapy. *J Am Geriatr Soc* 65(7): 1414-1419, 2017. PM28263373/PMC5507739
42. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, **Alumkal JJ**, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ: High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. *Clin Genitourin Cancer* 15(6): 733-741.e1, 2017. PM28655452
43. Tao DL, Bailey S, Beer TM, Foss E, Beckett B, Fung A, Foster BR, Guimaraes A, Cetnar JP, Graff JN, Eilers KM, Small EJ, Corless CL, Thomas GV, **Alumkal JJ**: Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making. *JCO Precis Oncol* 1: PO.16.00067, 2017. PM31650098/PMC6812573
44. Armstrong AJ, Halabi S, Healy P, **Alumkal JJ**, Winters C, Kephart J, Bitting RL, Hobbs C, Soleau CF, Beer TM, Slottke R, Mundy K, Yu EY, George DJ: Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. *Eur J Cancer* 81: 228-236, 2017. PM28502694/PMC6345641
45. Bryce AH, **Alumkal JJ**, Armstrong A, Higano CS, Iversen P, Sternberg CN, Rathkopf D, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer TM: Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. *Prostate Cancer Prostatic Dis* 20(2): 221-227, 2017. PM28117385/PMC5435962
46. Graff JN, **Alumkal JJ**, Beer TM: Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer? *JAMA Oncol* 3(1): 11-12, 2017. PM27812686
47. Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, **Alumkal JJ**, Beer TM, Thomas GV: Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. *Oncotarget* 8(42): 71447-71455, 2017. PM29069718/PMC5641061

48. Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, **Alumkal JJ**, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI: Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. *Clin Cancer Res* 23(14): 3544-3551, 2017. PM28213364/PMC5543693
49. King CJ, Woodward J, Schwartzman J, Coleman DJ, Lisac R, Wang NJ, Van Hook K, Gao L, Urrutia J, Dane MA, Heiser LM, **Alumkal JJ**: Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer. *Oncotarget* 8(67): 111084-111095, 2017. PM29340039/PMC5762307
50. Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, **Alumkal JJ**: DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. *J Natl Compr Canc Netw* 16(8): 933-937, 2018. PM30099369
51. Carlo MI, Giri VN, Paller CJ, Abida W, **Alumkal JJ**, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Ryan CJ, Schaeffer EM, Stadler WM, Taplin ME, Kauff ND, Vinson J, Antonarakis ES, Cheng HH: Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. *JCO Precis Oncol* 2018: 10.1200/PO.18.00060, 2018. PM30761386/PMC6370313
52. Sehrawat A, Gao L, Wang Y, Bankhead A 3rd, McWeeney SK, King CJ, Schwartzman J, Urrutia J, Bisson WH, Coleman DJ, Joshi SK, Kim DH, Sampson DA, Weinmann S, Kallakury BVS, Berry DL, Haque R, Van Den Eeden SK, Sharma S, Bearss J, Beer TM, Thomas GV, Heiser LM, **Alumkal JJ**: LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. *Proc Natl Acad Sci U S A* 115(18): E4179-E4188, 2018. PM29581250/PMC5939079
53. Chow M, Gao L, MacManiman JD, Bicocca VT, Chang BH, **Alumkal JJ**, Tyner JW: Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL. *Oncogene* 37(38): 5221-5232, 2018. PM29849118/PMC6150818
54. Mitri ZI, Parmar S, Johnson B, Kolodzie A, Keck JM, Morris M, Guimaraes AR, Beckett BR, Borate U, Lopez CD, Kemmer KA, **Alumkal JJ**, Beer TM, Corless CL, Mills GB, Gray JW, Bergan RC: Implementing a comprehensive translational oncology platform: from molecular testing to actionability. *J Transl Med* 16(1): 358, 2018. PM30551737/PMC6295039
55. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, **Alumkal JJ**, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell* 175(3): 889, 2018. PM30340047
56. Aggarwal R, Huang J, **Alumkal JJ**, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ: Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. *J Clin Oncol* 36(24): 2492-2503, 2018. PM29985747/PMC6366813
57. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, **Alumkal JJ**, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell* 174(3): 758-769.e9, 2018. PM30033370 /PMC6425931
58. Coleman DJ, Gao L, King CJ, Schwartzman J, Urrutia J, Sehrawat A, Tayou J, Balter A, Burchard J, Chiotti KE, Derrick DS, Sun D, Xia Z, Heiser LM, **Alumkal JJ**: BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. *Oncogene* 38(28): 5658-5669, 2019. PM30996246/PMC6677126

59. Ferrari AC, **Alumkal JJ**, Stein MN, Taplin ME, Babb J, Barnett ES, Gomez-Pinillos A, Liu X, Moore D, DiPaola R, Beer TM: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. *Clin Cancer Res* 25(1): 52-63, 2019. PM30224345
60. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, **Alumkal JJ**, West Coast Prostate Cancer Dream Team.: Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. *Eur Urol* 76(5): 562-571, 2019. PM30928160/PMC6764911
61. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, **Alumkal JJ**, Reiter RE, Rettig MB: MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. *Prostate Cancer Prostatic Dis* 22(4): 531-538, 2019. PM30804427 /PMC6853839
62. Reichert ZR, Urrutia J, **Alumkal JJ**: Microsatellite Instability as an Emerging Biomarker for Checkpoint Inhibitor Response in Advanced Prostate Cancer. *JAMA Oncol* 5(4): 478-479, 2019. PM30589921
63. Aggarwal R, Huang J, **Alumkal J**, Feng FY, Zhang L, Stuart JM, Small EJ: Reply to A. Dalla Volta et al. *J Clin Oncol* 37(4): 351-352, 2019. PM30557523
64. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, **Alumkal JJ**, Small EJ: Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. *Mol Cancer Res* 17(6): 1235-1240, 2019. PM30918106 /PMC6548614
65. Coleman DJ, Gao L, Schwartzman J, Korkola JE, Sampson D, Derrick DS, Urrutia J, Balter A, Burchard J, King CJ, Chiotti KE, Heiser LM, **Alumkal JJ**: Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer. *Sci Rep* 9(1): 3823, 2019. PM30846826/PMC6405739
66. Ferrari AC, **Alumkal JJ**, Stein MN, Taplin ME, Babb J, Barnett ES, Gomez-Pinillos A, Liu X, Moore D, DiPaola R, Beer TM: Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. *Clin Cancer Res* 25(8): 2672, 2019. PM30988096
67. Turina CB, Coleman DJ, Thomas GV, Fung AW, **Alumkal JJ**: Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer. *Cureus* 11(7): e5197, 2019. PM31565603/PMC6758987
68. Gao B, Lue HW, Podolak J, Fan S, Zhang Y, Serawat A, **Alumkal JJ**, Fiehn O, Thomas GV: Multi-Omics Analyses Detail Metabolic Reprogramming in Lipids, Carnitines, and Use of Glycolytic Intermediates between Prostate Small Cell Neuroendocrine Carcinoma and Prostate Adenocarcinoma. *Metabolites* 9(5): 82, 2019. PM31035489/PMC6572715
69. Singh KB, Hahm ER, **Alumkal JJ**, Foley LM, Hitchens TK, Shiva SS, Parikh RA, Jacobs BL, Singh SV: Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane. *Carcinogenesis* 40(12): 1545-1556, 2019. PM31555797/PMC7175465
70. Graff JN, Beer TM, **Alumkal JJ**, Slottke RE, Redmond WL, Thomas GV, Thompson RF, Wood MA, Koguchi Y, Chen Y, Latour E, Bergan RC, Drake CG, Moran AE: A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. *J Immunother Cancer* 8(2): 10.1136/jitc-2020-000642, 2020. PM32616555 /PMC7333874
71. Coleman DJ, Sampson DA, Sehrawat A, Kumaraswamy A, Sun D, Wang Y, Schwartzman J, Urrutia J, Lee AR, Coleman IM, Nelson PS, Dong X, Morrissey C, Corey E, Xia Z, Yates JA, **Alumkal JJ**: Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. *Neoplasia* 22(6): 253-262, 2020. PM32403054/PMC7218227
72. Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, **Alumkal JJ**, Gleave M, Chi KN, Reiter RE, Rettig MB, Evans CP, Small EJ, Sharifi N, Zhao SG: Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. *Prostate Cancer Prostatic Dis* 23(2): 316-323, 2020. PM31745256

73. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, **Alumkal JJ**, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY: The DNA methylation landscape of advanced prostate cancer. *Nat Genet* 52(8): 778-789, 2020. PM32661416
74. Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, Rettig M, Schultz N, Smith M, Solit D, Sternberg C, Van Allen E, VanderWeele D, Vinson J, Soule HR, Chinnaiyan A, Small E, Simons JW, Dahut W, Miyahira AK, Beltran H: Accelerating precision medicine in metastatic prostate cancer. *Nat Cancer* 1(11): 1041-1053, 2020. PM34258585/PMC8274325
75. Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, **Alumkal JJ**, Rettig M, Gleave M, Lara PN Jr, Thomas GV, Li P, Lui A, Small EJ, Aggarwal RR: Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. *Urol Oncol* 12: 931, 2020. PM32624423
76. **Alumkal JJ**, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z: Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. *Proc Natl Acad Sci U S A* 117(22): 12315-12323, 2020. PM32424106/PMC7275746
77. Spratt DE, Malone S, Roy S, Grimes S, Eapen L, Morgan SC, Malone J, Craig J, Dess RT, Jackson WC, Hartman HE, Kishan AU, Mehra R, Kaffenberger S, Morgan TM, Reichert ZR, **Alumkal JJ**, Michalski J, Lee WR, Pisansky TM, Feng FY, Shipley W, Sandler HM, Schipper MJ, Roach M, Sun Y, Lawton CAF: Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. *J Clin Oncol* 2: 136-144, 2020. PM33275486
78. Reichert ZR, Jones MA, **Alumkal JJ**: A CHIP in the Armor of Cell-Free DNA-Based Predictive Biomarkers for Prostate Cancer. *JAMA Oncol* 1: 111-112, 2020. PM33151257
79. Smith R, Liu M, Liby T, Bayani N, Bucher E, Chiotti K, Derrick D, Chauchereau A, Heiser L, **Alumkal J**, Feiler H, Carroll P, Korkola JE: Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. *Sci Rep* 10(1): 21750, 2020. PM33303959/PMC7729982
80. Cackowski FC, Kumar-Sinha C, Mehra R, Wu YM, Robinson DR, **Alumkal JJ**, Chinnaiyan AM: Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study. *JCO Precis Oncol* 4: PO.20.00309, 2020. PM33283137/PMC7713564
81. Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, Lakhota S, Feng FY, Small EJ, Abida W, **Alumkal JJ**: A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer. *Clin Cancer Res* 20: 5338-5347, 2020. PM32694156
82. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, **Alumkal JJ**, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY: Autoantibody Landscape in Patients with Advanced Prostate Cancer. *Clin Cancer Res* 23: 6204-6214, 2020. PM32967941
83. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P Jr, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, **Alumkal JJ**: Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res* 17: 4616-4624, 2020. PM32727885

84. Joaquin Mateo, Rana McKay, Wassim Abida, Rahul Aggarwal, **Joshi Alumkal**, Ajjai Alva, Felix Feng, Xin Gao, Julie Graff, Maha Hussain, Fatima Karzai, Bruce Montgomery, William Oh, Vaibhav Patel, Dana Rathkopf, Matthew Rettig, Nikolaus Schultz, Matthew Smith, David Solit, Cora Sternberg, Eliezer Van Allen, David VanderWeele, Jake Vinson, Howard R. Soule, Arul Chinnaiyan, Eric Small, Jonathan W. Simons, William Dahut, Andrea K. Miyahira and Himisha Beltran: Accelerating precision medicine in metastatic prostate cancer *Nature Cancer* 1: 1041–1053, 2020.
85. Gharzai LA, Jiang R, Wallington D, Jones G, Birer S, Jairath N, Jaworski EM, McFarlane MR, Mahal BA, Nguyen PL, Sandler H, Morgan TM, Reichert ZR, **Alumkal JJ**, Mehra R, Kishan AU, Fizazi K, Halabi S, Schaeffer EM, Feng FY, Elliott D, Dess RT, Jackson WC, Schipper MJ, Spratt DE: Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. *Lancet Oncol* 22(3): 402-410, 2021. PM33662287
86. Labrecque MP, **Alumkal JJ**, Coleman IM, Nelson PS, Morrissey C: The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. *Endocr Relat Cancer* 10: 1530, 2021. PM33792558
87. Abdulfatah E, Reichert ZR, Davenport MS, Chinnaiyan AM, Dadhania V, Wang X, Mannan R, Kunju LP, Hollenbeck BK, Montgomery JS, Kaffenberger SD, Morgan TM, Alva AS, Palapattu GS, Vaishampayan UN, **Alumkal JJ**, Spratt DE, Udager AM, Mehra R: De novo neuroendocrine transdifferentiation in primary prostate cancer—a phenotype associated with advanced clinico-pathologic features and aggressive outcome. *Med Oncol* 38(3): 26, 2021. PM33586037
88. Kim DH, Sun D, Storck WK, Welker Leng KR, Jenkins C, Coleman DJ, Sampson DA, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman J, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman I, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead A, Rao A, Gesner EM, Atwell S, Lakhota S, Campeau E, Yates JA, Xia Z, **Alumkal JJ**: BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. *Clin Cancer Res* 10: 1078-0432, 2021. PM34145028
89. Labrecque MP, Brown LG, Coleman IM, Lakely B, Brady NJ, Lee JK, Nguyen HM, Li D, Hanratty B, Haffner MC, Rickman DS, True LD, Lin DW, Lam HM, **Alumkal JJ**, Corey E, Nelson PS, Morrissey C: RNA splicing factors SRRM3 and SRRM4 distinguish molecular phenotypes of castration-resistant neuroendocrine prostate cancer. *Cancer Res* 10: 1158/0008, 2021. PM34312180
90. Kumaraswamy A, Welker Leng KR, Westbrook TC, Yates JA, Zhao SG, Evans CP, Feng FY, Morgan TM, **Alumkal JJ**: Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. *Eur Urol* 10: 1016, 2021. PM33785255

Abstracts

1. Guo M, **Alumkal J**, Drachova T, Jen J, Herman J: CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non small cell lung cancer, *Cancer Res*, 67, 383, 2007.
2. **Alumkal JJ**, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, Partin AW, Garrett-Mayer E, DeMarzo AM, Herman JG: The impact of DNA methylation on the identification of recurrent prostate cancer, *Proc Amer Soc Clin Onc*, 736, 21086, 2007.
3. **Alumkal JJ**, Zhang Z, Carducci MA, Partin AW, Garrett-Mayer E, DeMarzo AM, Herman JG: DNA methylation as a predictor of prostate cancer recurrence, *Proc GU Ca Symp*, 128, 66, 2008.
4. Higano C, **Alumkal J**, Ryan CJ, Yu EY, Beer TM, Chandrawansa K, Katz T, Youssoufian H, Schwartz J: A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastatic, asymptomatic castration-resistant prostate cancer (CRPC)., *J Clin Oncol*, 27, 15, 2009.
5. Rathkopf DE, Chi KN, Vaishampayan U, Hotte S, Vogelzang N, **Alumkal J**, Agrawal M, Nydam TM, Fandi A, Scher HI.: Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC), *J Clin Onc*, 27, 15, 2009.
6. Vaishampayan U, Rathkopf D, Chi KN, Hotte S, Vogelzang N, **Alumkal J**, Agrawal M, Picus J, Nydam T, Fandi A, Scher HI: Phase 1b Dose-finding Trial of Intravenous (i.v.) Panobinostat with Docetaxel and Prednisone in Patients with Castration-resistant Prostate Cancer (CRPC), *Proc Joint 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO)*, 2009.

7. Mori M, Chen Y, **Alumkal J**: Estimation of Safe and Effective Dose in Phase I Clinical Trials in Oncology, Proc Joint Statistical Meeting, 2009.
8. Gibbs A, Schwartzman J, Deng V, **Alumkal J**: Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating HDAC6, Proc National Cancer Institute (NCI) Translational Science Meeting. Proc National Cancer Institute (NCI) Translational Science Meeting, 2009.
9. Schwartzman J, Mongoue-Tchokote S, Zarour L, DeMarzo A, Bova GS, Mori M, **Alumkal J**: A microarray-based study of DNA methylation changes in prostate cancer, Proc Prostate Cancer Foundation Scientific Retreat, 1, 2009.
10. Mongoue-Tchokote S, Mori M, **Alumkal J**: Statistical Issues in High-Throughput Genome-Wide DNA Methylation Studies, Proc WNAR Biometric Meeting, 2009.
11. Gibbs A, Schwartzman J, Deng V, Perepechaev A, Alumkal J: Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating HDAC6, Cancer Res, 69, 4, 2009.
12. Schwartzman J, Mongoue-Tchokote S, Zarour L, DeMarzo A, Bova GS, Mori M, **Alumkal JJ**: A microarray-based study of DNA methylation changes in prostate cancer, Cancer Res, 70, 144, 2010.
13. Small EJ, Beer TM, Weinberg VK, Higano CS, Nordquist LT, Rosenberg JE, **Alumkal JJ**, Yu EY, Sun J, Lin AM: Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium, J Clin Oncol, 15, 4684, 2010.
14. Rathkopf DE, Vaishampayan U, Chi KN, **Alumkal J**, Hotte SJ, George DJ, Agrawal M, Picus J, Hu J, Savage P, Nydam T, Hirawat S, Scher HI: A Phase I Dose-finding Trial of Intravenous (i.v.) Panobinostat with Docetaxel and in Patients with Castration-resistant Prostate Cancer (CRPC), Proc GU Ca Symp, 147, 2010.
15. Higano CS, **Alumkal JJ**, Ryan CJ, Yu EY, Beer TM, Fox FE, Dontabhaktuni A, Youssoufian H, Schwartz JD: A Phase II Study of Cixutumumab (IMC-A12), a Monoclonal Antibody (MAb) Against the Insulin-like Growth Factor 1 Receptor (IGF-IR), Monotherapy in Metastatic Castration-resistant Prostate Cancer (MCRPC): Feasibility of Every 3-week Dosing and Updated Results, Proc GU Ca Symp, 189, 2010.
16. Small EJ, Beer TM, Weinberg VK, Higano CS, **Alumkal JJ**, Yu EY, Nordquist LT, Rosenberg JE, Sun J, Lin AM: Intermittent chemotherapy (ICh) for metastatic androgen deprivation resistant prostate cancer (mADRPC): Results of a prospective randomized phase 2 trial of the dod prostate cancer clinical trials consortium, Proc GU Ca Symp, 41, 2010.
17. Mori M, Chen Y, Park BS, **Alumkal J**: Genotype-Stratified Phase I Trials in Oncology, Proc International Biometric Society, 2010.
18. Ferrari C, Stein MN, **Alumkal JJ**, Gomez-Pinillos A, Catamero DD, Mayer TM, Collins F, Beer TM, DiPaola RS: A phase I/II randomized study of panobinostat and bicalutamide in castration-resistant prostate cancer (CRPC) patients progressing on second-line hormone therapy, J Clin Oncol, 7, 156, 2011.
19. Small E, Lin AM, Beer TM, Weinberg VK, Higano CS, Nordquist L, Rosenberg JE, **Alumkal J**, Yu EY, Mi J, Harzstark AL: Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium, Innovative Minds Prost Ca Today (IMPACT), P19-56, 2011.
20. Harzstark L, Beer TM, Weinberg VK, Higano CS, Nordquist LT, Rosenberg JE, **Alumkal JJ**, Yu EY, Mi J, Small EJ: Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium, J Clin Oncol, 7, 133, 2011.
21. Garzotto M, Hung A, Beer TM, **Alumkal JJ**, Graff JN, Farris PE, Flamiatos JF, Mongoue-Tchokote S, Carter SN: Phase I/II study of neoadjuvant docetaxel plus intensity-modulated radiotherapy (IMRT) prior to surgery for high-risk prostate cancer, J Clin Oncol, 4662, 2011.
22. Ryan CJ, Rosenthal M, Ng S, **Alumkal JJ**, Picus J, Gravis G, Fizazi K, Forget F, Machiels J H, Zhu M, Jiang J, Dubey S, Loh E, Gerritsen W R: A multicenter, randomized phase 2 study of rilutumumab (AMG 102) or placebo plus mitoxantrone and prednisone in patients with previously treated castrate-resistant prostate cancer, J Clin Oncol, 5, 115, 2012.
23. Hussain M, Corn PG, Michaelson D, Hammers HJ, **Alumkal JJ**, Ryan CJ, Bruce JY, Moran S, Lee SY, Mortimer P, George DJ.: A phase 2 multicenter study of the investigational single agent orteronel (ortl, TAK-700) in nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA), European Urology Supplements, 5, P115, 230-231, 2012.

24. Rathkopf DE, Shore N, Antonarakis ES, Berry WR, **Alumkal JJ**, Tutrone R, Saleh MN, Redfern CH, Hauke RJ, Liu G, Steinbrecher JE, Costin-Danila D, Curley T, Arauz G, Rix PJ, Chow-Maneval E, Chen I, Scher HI: A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC), *J Clin Oncol*, TPS4697, 2012.
25. Small EJ, Winberg VK, Ryan CJ, Higano CS, Lin AM, Maruca Y, **Alumkal JJ**, Yu EY, Rosenberg JE, Beer TM: A prospective randomized phase II trial evaluating maintenance GM-CSF in an intermittent chemotherapy (chemo) regimen for metastatic castration-resistant prostate cancer (mCRPC): A DoD prostate cancer clinical trials consortium trial, *J Clin Oncol*, 35, 2012.
26. Rathkopf DE, Antonarakis ES, Shore ND, Tutrone R, **Alumkal JJ**, Ryan CJ, Saleh MN, Hauke RJ, Maneval EC, Scher HI.: ARN-509 in men with metastatic castration-resistant prostate cancer (CRPC), *Proc ESMO Congress 2012*, 964TiP, 2012.
27. Rathkopf DE, Antonarakis ES, Shore ND, Tutrone R, **Alumkal J**, Ryan CJ, Saleh M, Hauke R, Chow Maneval E, Scher HI: ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC), *J Clin Oncol*, 6, 48, 2012.
28. Hussain M, Corn P, Michaelson D, Hammers H, **Alumkal J**, Ryan C, Bruce J, Moran S, Mortimer P, Lee S.Y., George D.: Activity and safety of the investigational agent orteronel (ortl, TAK-700) in men with nonmetastatic castration-resistant prostate cancer (CRPC) and rising prostate-specific antigen (PSA): Results of a phase 2 study. *Proc 27th Annual Congress of the European Association of Urology (EAU)*, 2012.
29. Slovin SF, Hamid O, Tejwani S, Higano CS, Harzstark A, **Alumkal JJ**, Scher HI, Chin KM, Gagnier P, McHenry MB, Beer TM: Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study, *J Clin Oncol*, 5, 25, 2012.
30. Hussain M, Carducci MA, Slovin SF, Cetnar JP, Qian J, McKeegan EM, Litvinovich E, Chyla B, Hetman R, Desai B, Giranda VL, **Alumkal JJ**: Pilot study of veliparib (ABT-888) with temozolomide (TMZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC), *J Clin Oncol*, 5, 224, 2012.
31. Gao L, Schwartzman J, Gibbs A, Kleinschmidt R, Bottomly D, Wilmot B, Bankhead A, Zhang X, Vessella R, McWeeney S, **Alumkal JJ**.: LSD1 promotes castration-resistant prostate cancer progression, *Proc Prostate Cancer Foundation Scientific Retreat*, 2012.
32. George DJ, Corn PG, Michaelson MD, Hammers HJ, **Alumkal JJ**, Ryan CJ, Bruce JY, Moran S, Lee SY, Mortimer P, Hussain M: Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study, *J Clin Oncol*, 4549, 2012.
33. Gao L, Schwartzman J, Wilmot B, Bottomly D, Gibbs A, Kleinschmidt R, McWeeney S, **Alumkal J**: The Androgen Receptor Promotes Androgen-Independent Prostate Cancer Cell Survival through Up-regulation of c-Myc. *Proc Oregon Clinical and Translational Research Institute (OCTRI) Research Week*, 2012.
34. Omlin GA, Jones RJ, van der Noll R, Graham J, Ong M, Finkelman RD, Schellens J HM, Zivi A, Crespo M, Clack G, **Alumkal JJ**, Dymond A, Dickinson A, Ranson M, Malone MD, De Bono JS, Elliott T.: A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC), *J Clin Oncol*, 4511, 2013.
35. Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore N, Liu G, **Alumkal JJ**, Higano CS, Maneval EC, Rathkopf DE.: ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC), *J Clin Oncol*, 6, 7, 2013.
36. Gao L, Schwartzman J, Gibbs A, Kleinschmidt R, Wilmot B, Bottomly D, Coleman I, Nelson P, McWeeney S, **Alumkal J**.: Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression Through c-Myc Upregulation, *Cancer Res*, 73, 3131, 2013.
37. Yu EY, Duan F, Muzi M, Gorelick J, Chin B, **Alumkal JJ**, Taplin ME, Herman B, Higano CS, Doot RK, Hartfeil DM, Febbo FG, Mankoff DA: Correlation of 18F-fluoride PET response to dasatinib in castration-resistant prostate cancer bone metastases with progression-free survival: Preliminary results from ACRIN 6687, *J Clin Oncol*, 5003, 2013.
38. Van Hook K, Lisac R, Schwartzman J, Heiser L, King C, Rantala J, Wang N, **Alumkal J**: Identifying Emergent MDV-3100 Resistance Mechanisms, *Proc OHSU Knight Cancer Institute Annual Retreat*, 2013.
39. Gao L, Schwartzman J, Gibbs A, Bottomly D, Wilmot B, McWeeney S, **Alumkal J**: A functional genomics approach to identify molecular markers of aggressive prostate cancer, *Proc Prostate Cancer Foundation Scientific Retreat*, 2013.

40. Hussain M, Corn PG, Michaelson MD, Hammers HJ, **Alumkal JJ**, Ryan CJ, Bruce JY, Moran S, MacLean D, Lee S-Y, Lin HM, Zhu Y, Shi H, Mortimer P, George DJ.: Safety, efficacy, and health-related quality of life (HRQoL) of the investigational single agent orteronel (ortl) in nonmetastatic castration-resistant prostate cancer (nmCRPC), *J Clin Oncol*, 5076, 2013.
41. **Alumkal JJ**, Slottke R, Mori M, Schwartzman J, Graff N, Beer, TM, Ryan CW, Koop DR, Cherala G, Munar M, Flamiatos JF, Gao L, Tucker E: Sulforaphane treatment in men with recurrent prostate cancer, *J Clin Oncol*, 31, 5017, 2013.
42. **Alumkal JJ**, Heiser L, Beer TM, Small E, Baertsch R, Stuart J, King C, Korkola J, Cetnar J, Graff J, Thomas G, Ryan C, Toschi A, Youngren J, Tucker E, Eilers K: AACR/PCF/Stand Up to Cancer West Coast Prostate Cancer Dream Team. Identifying enzalutamide resistance mechanisms in men with castration-resistant prostate cancer, *J Clin Oncol*, TPS5104, 2014.
43. Rathkopf DE, Antonarakis ES, Shore ND, Tutrone R, **Alumkal JJ**, Ryan CJ, Saleh MN, Hauke RJ, Bandekar R, Maneval EC, de Boer C, Todd M, Yu MK, Scher HI: ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment, *J Clin Oncol*, 5026, 2014.
44. Rathkopf DE, Antonarakis ES, Shore ND, Tutrone R, **Alumkal JJ**, Ryan CJ, Saleh MN, Hauke RJ, Bandekar R, Maneval EC, de Boer C, Todd M, Yu MK, Scher HI: ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA), *Cancer Res*, 74, CT239, 2014.
45. Small EJ, Youngren J, Thomas G, Olson S, Toschi A, Foye A, **Alumkal JJ**, Rettig M, Gleave ME, Evans CP, Stuart J, Ryan CJ, Reiter RE, Chi KN, Lara P, Beer TM, PCF/SU2C/AACR West Coast Prostate Cancer Dream Team: Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT), *J Clin Oncol*, 5020, 2014.
46. Thomas G, Youngren J, Ryan CW, Beer TM, Gleave ME, Evans CP, Stuart J, Rettig M, Toschi A, Foye A, **Alumkal JJ**, Corless CL, Neff T, Baertsch R, Huang J, Chi KN, Lam KS, Goldstein TC, Witte O, Small EJ: Molecular profiling of metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT), *J Clin Oncol*, 5088, 2014.
47. Small EJ, Youngren J, **Alumkal J**, Evan C, Ryan CJ, Lara P, Beer T, Witte O, Baertsch R, Stuart J: Neuroendocrine prostate cancer (NEPC) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT), *Proc ESMO*, 760PD, 2014.
48. Bivol A, Baertsch R, Sokolov A, Paull E, Newton Y, Goldstein TC, Foye A, Pourmand N, Youngren J, Parulkar R, Lopez A, de Vere White R, **Alumkal JJ**, Toschi A, Beer TM, Evans CP, Gleave ME, Witte O, Small EJ, Stuart JM: Pathway-based signature analysis of RNA-seq data to reveal new targetable avenues for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT), *J Clin Oncol*, 11078, 2014.
49. King C, Coleman D, Lisac R, Schwartzman J, Wang N, Gleave M, Thomas G, Beer T, Van Hook K, Korkola J, Gao L, Heiser L, **Alumkal JJ**: Integrative Genomic Analysis to Identify Emergent Enzalutamide Resistance Mechanisms in Castration-Resistant Prostate Cancer, *Proc Prostate Cancer Foundation Scientific Retreat*, 006, 2014.
50. Higano C, **Alumkal J**, Chowdhury S, Lorient Y, Sternberg C, De Bono J, Tombal B, Carles J, Perabo F, Forer D, Noonberg S, Mansbach H, Beer TM: Response rates and outcomes with enzalutamide for patients with metastatic castration resistant prostate cancer and visceral disease in the PREVAIL trial, *Proc ESMO*, 767P, 2014.
51. Small EJ, Youngren J, Beer TM, Ryan CJ, Thomas G, Pourmand N, Reiter RE, **Alumkal JJ**, Stuart JM, Evans CP, Gleave ME, Chi KN, Toschi A, Foye A, Lara P, Witte O: SU2C/PCF/AACR West Coast Prostate Cancer Dream Team. The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT), *J Clin Oncol*, 4, 79, 2014.
52. Aggarwal RR, Thomas G, Youngren J, Foye A, Olson S, Paris P, Beer TM, Ryan CJ, Witte O, Evans CP, Gleave ME, Stuart J, **Alumkal JJ**, Toschi A, Zona N, Reiter RE, Lara P, Chi KN, Small EJ: Androgen receptor (AR) amplification in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT), *J Clin Oncol*, 5068, 2015.

53. Rathkopf DE, Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Higano C, **Alumkal JJ**, Hauke R, Tutrone R, Saleh M, Maneval EC, Thomas S, Ricci D, Yu MK, de Boer CJ, Trinh A, Kheoh T, Bandekar R, Scher HI: Androgen receptor (AR) mutation in patients (pts) with castration-resistant prostate cancer (CRPC) with and without prior abiraterone acetate (AA) treatment, Cancer Res, CT134, 2015.
54. Coleman D, Van Hook K, Lisac R, King C, Wang N, Schwartzman J, Gleave M, Gao L, Urrutia J, Heiser L, **Alumkal JJ**: Androgens interfere with enzalutamide agonism of mutant F876L androgen receptor, Cancer Res, 3592, 2015.
55. Small EJ, Huang J, Youngren J, Sokolov A, Aggarwal RR, Thomas G, True LD, Zhang L, Foye A, **Alumkal JJ**, Ryan CJ, Rettig M, Evans CP, Gleave ME, Baertsch R, Stuart J, Reiter RE, Lara P, Chi KN, Beer TM: Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT), J Clin Oncol, 5003, 2015.
56. Woodward J, King C, Coleman D, Lisac R, Schwartzman J, Wang N, Gleave M, Gray J, Thomas G, Beer TM, Van Hook K, Baertsch R, Goldstein T, Stuart J, Gao L, Urrutia J, Heiser L, **Alumkal JJ**: Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer, Cancer Res, 731, 2015.
57. Ferrari AC, **Alumkal JJ**, Stein MN, Mayer TM, Torneten S, Babb J, Taplin ME, DiPaola RS, Beer TM.: LBH589 (LBH) and bicalutamide (Bic) in castration-resistant prostate cancer (CRPC) patients (pts) progressing on second line anti-androgen (AA): NYU-08479/PCCTC, J Clin Oncol, 5050, 2015.
58. Gao L, Bankhead III A, Heiser L, King C, Schwartzman J, Wang NJ, Korkola J, Gray JW, Weinmann S, Kallakury BVS, Haque R, Van Den Eeden SK, Gulati R, Beer TM, Sharma S, Bearss J, Thomas GV, McWeeney S, **Alumkal JJ**: LSD1 promotes castration-resistant prostate cancer progression, Proc 2015 Pac Rim Conference, 2015.
59. Armstrong AJ, Halabi S, Healy P, **Alumkal JJ**, Yu EY, Winters C, Hobbs C, Soleau C, Slottke R, Mundy K, George DJ: Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC), J Clin Oncol, TPS5084, 2015.
60. Coleman DJ, Van Hook K, Woodward J, Lisac R, King C, Wang N, Schwartzman J, Gleave M, Korkola J, Gao L, Heiser L, **Alumkal JJ**: Clarification of Mechanisms that Influence Enzalutamide Agonism of Mutant F876L Androgen Receptor, Proc 2015 Pac Rim Conference, 2015.
61. Sternberg CN, Higano CS, **Alumkal J**, Chowdhury S, Loriot Y, De Bono JS, Tombal B, Carles J, Perabo F, Forer D, Noonberg SB, Mansbach H, Beer TM: Response rates and outcomes with enzalutamide for patients with metastatic castration-resistant prostate cancer and visceral disease in the PREVAIL trial, Proc PROSCA 2015 Global Congress, 2015.
62. Danila DC, Kuzel T, Cetnar JP, Rathkopf DE, Morris MJ, **Alumkal JJ**, Butler A, Curley T, Hullings M, Buddle JR, Filipenko J, Scher HI: A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy- and immunotherapy-naïve patients with progressive metastatic castration resistant prostate cancer (mCRPC), J Clin Oncol, e16507, 2016.
63. Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave ME, Korkola JE, Gao L, Heiser LM, **Alumkal JJ**: Androgen content and BET bromodomain proteins influence enzalutamide agonism of mutant F876L androgen receptor, J Clin Oncol, e16538, 2016.
64. Gao L, Coleman DJ, King CJ, Schwartzman J, Wang N, Esch A, Urrutia J, Sehrawat A, Heiser LM, **Alumkal JJ**: BET bromodomain inhibition is a promising treatment strategy for distinct subsets of lethal castration-resistant prostate cancer, Cancer Res, 4700, 2016.
65. Small EJ, Aggarwal RR, Huang J, Sokolov A, Zhang L, **Alumkal JJ**, Youngren J, Ryan CJ, Foye A, Reiter RE, Evans CP, Gleave M, Witte O, Stuart J, Goldstein TC, Thomas GV, True LD, Beltran H, Rubin MA, Beer TM: Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT), J Clin Oncol, 5019, 2016.
66. Kim W, Ryan CJ, Zhang L, Youngren J, Wilton J, **Alumkal JJ**, Beer TM, Baertsch R, Stuart J, Chi KN, Gleave M, Rettig M, Reiter RE, Lara P, Evans CP, Small EJ: Dehydroepiandrosterone (DHEA) in metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Dream Team (WCDT), J Clin Oncol, e16598, 2016.
67. Kim W, Ryan CJ, Zhang L, Youngren J, Wilton J, **Alumkal JJ**, Beer TM, Baertsch R, Stuart J, Chi KN, Gleave M, Rettig M, Reiter RE, Lara P, Evans CP, Small EJ: Dehydroepiandrosterone in metastatic castration-resistant prostate cancer: Preliminary results from the SU2C-PCF West Coast Dream Team (WCDT), J Clin Oncol, 179, 2016.

68. Aggarwal RR, Youngren J, Sokolov A, Huang J, Thomas GV, True LD, Foye A, **Alumkal JJ**, Ryan CJ, Beer TM, Evans CP, Gleave M, Rettig M, Stuart JM, Lara P, Goldstein TC, Zhang L, Reiter RE, Chi KN, Small EJ: Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT), J Clin Oncol, 5045, 2016.
69. Aggarwal RR, Youngren J, Sokolov A, Huang J, Thomas G, Foye A, **Alumkal JJ**, Ryan CJ, Beer TM, Evans CP, Gleave M, Rettig M, Small EJ: Persistence of androgen receptor (AR) expression in patients (pts) with small cell prostate cancer (SCPC): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT), J Clin Oncol, 288, 2016.
70. Sehrawat A, Gao L, Tayou J, Bankhead III A, Heiser LM, King CJ, Wang Y, Schwartzman J, Urrutia J, Coleman DJ, Weinmann S, Kallakury BVS, Berry DL, Haque R, Van Den Eeden SK, Beer TM, Thomas GV, McWeeney S, **Alumkal JJ**: LSD1 promotes castration-resistant prostate cancer cell survival independently of the androgen receptor and of histone demethylation, Proc Ann AACR Mtg, 2406, 2017.
71. **Alumkal, J**: BET Bromodomain Inhibition is a Promising Treatment Strategy for Distinct Subsets of Lethal Prostate Cancer, Proc Keystone Symp Epi Human Dis, 1004, 2017.
72. Sehrawat A, Gao L, Wang Y, Bankhead III A, McWeeney S, King CJ, Schwartzman J, Tayou J, Urrutia J, Bisson WH, Coleman DJ, Joshi SK, Weinmann S, Kallakury BVS, Berry DL, Haque R, Van Den Eeden SK, Sharma S, Bearss J, Beer TM, Thomas GV, Heiser LM, **Alumkal JJ**: LSD1 Activates a Lethal Prostate Cancer Gene Network Independently of Its Demethylase Function, Annual Multi-Institutional PPCR/SPORE Mtg, 42, 2018.
73. Kim W, Small EJ, Aggarwal RR, Den RB, Lehrer J, Zhang L, Youngren J, Goldstein TC, **Alumkal JJ**, Gleave M, Rettig M, Evans CP, Beer TM, Reiter RE, Huang J, Thomas GV, Davicioni E, Ryan CJ, Spratt DE, Feng FY: Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications, GU ASCO Mtg, 197, 2018.
74. Aggarwal RR, Zhang L, Beer TM, Youngren J, Stromlund A, Bell A, Foye A, Playdle D, **Alumkal JJ**, Reiter RE, Gleave M, Evans CP, Thomas GV, Huang J, True LD, Rettig M, Lara P, Chi KN, Small EJ: Serum neuroendocrine (NE) markers and clinical characteristics of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) in men with metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team, GU ASCO Mtg, 278, 2018.
75. Sehrawat A, Kim D, Gao L, Wang Y, Bankhead III A, McWeeney S, King CJ, Schwartzman J, Tayou J, Urrutia J, Bisson WH, Coleman DJ, Joshi SK, Sampson DA, Weinmann S, Kallakury BVS, Berry DL, Haque R, Van Den Eeden SK, Sharma S, Bearss J, Beer TM, Thomas GV, Heiser LM, **Alumkal JJ**: LSD1 activates a lethal prostate cancer gene network independently of its demethylase function, Proc Ann AACR Mtg, LB-240, 2018.
76. Chen WS, Aggarwal RR, Zhang L, Zhao S, Beer TM, Quigley D, Foye A, Playdle D, Lloyd P, Rettig M, Gleave M, Evans CP, Lara P, Kothari V, Chi KN, Reiter RE, Maher C, Feng FY, Small EJ, **Alumkal JJ**: Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer, GU ASCO Mtg, 146, 2019.
77. Aggarwal R, Abida W, Schweizer M, Pantuck A, Nanus D, Heath E, Lakhota S, Hansen H, Silverman M, Bauman L, Snyder M, Campeau E, Norek K, Attwell S, O'Farrell M, Smith S, Wegge P, Jahagirdar R, **Alumkal JJ**: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC), Proc Ann AACR Mtg, CT095, 2019.
78. Eric Jay Small, Shuang Zhao, William S. Chen, Haolong Li, Adam Foye, Martin Sjöström, Jun Jie Hua, Rahul Raj Aggarwal, **Joshi J. Alumkal**, Tomasz M. Beer, Martin Gleave, Matthew Rettig, Owen Witte, Primo Lara, Arul Chinnaiyan, Chris Maher, David A. Quigley, Felix Y Feng: The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT)., 2020 ASCO Virtual Scientific Program, 2020.
79. Rahul Raj Aggarwal, **Joshi J. Alumkal**, Russell Zelig Szmulewitz, Celestia S. Higano, Alan Haruo Bryce, Angela Lopez-Gitlitz, Sharon Anne McCarthy, Branko Miladinovic, Kelly McQuarrie, Shibu Thomas, Eric Jay Small: A randomized phase II study of apalutamide (APA), androgen deprivation therapy (ADT), or APA + ADT in patients (pts) with biochemically relapsed (BCR) prostate cancer (PC)., 2020 Genitourinary Cancers Symposium, J Clin Oncol 38, 2020.

80. Daniel Kwon, Li Zhang, Adam Foye, William S. Chen, Felix Y Feng, Adina Bailey, Jiaoti Huang, David A. Quigley, Josh Stuart, Verena Friedl, Alana Weinstein, Tomasz M. Beer, **Joshi J. Alumkal**, Matthew Rettig, Martin Gleave, Primo Lara, Patricia Li, Austin Lui, Eric Jay Small, Rahul Raj Aggarwal: ADRB2 expression in progressive metastatic castration-resistant prostate cancer, 2020 Genitourinary Cancers Symposium, Virtual, J Clin Oncol, 38, 2020.
81. Daniel Kwon, Li Zhang, Adam Foye, William S. Chen, Felix Y Feng, Adina Bailey, Jiaoti Huang, David A. Quigley, Josh Stuart, Verena Friedl, Alana Weinstein, Tomasz M. Beer, **Joshi J. Alumkal**, Matthew Rettig, Martin Gleave, Primo Lara, Patricia Li, Austin Lui, Eric Jay Small, Rahul Raj Aggarwal: ADRB2 expression in progressive metastatic castration-resistant prostate cancer., 2020 Genitourinary Cancers Symposium, J Clin Oncol, 6, 145, 2020.
82. Eric Jay Small, Rahul Raj Aggarwal, Verena Friedl, Alana Weinstein, George V. Thomas, Lawrence D. True, Adam Foye, Tomasz M. Beer, Matthew Rettig, Martin Gleave, Christopher P. Evans, **Joshi J. Alumkal**, Robert Evan Reiter, Primo Lara, Kim N. Chi, Felix Y Feng, Adina Bailey, Josh Stuart, Jiaoti Huang: Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)-Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT), 2020 Genitourinary Cancers Symposium, 2020.
83. Julie Nicole Graff, Heather H. Cheng, Jacqueline Vuky, **Joshi J. Alumkal**, Dustin Kreitner, Delia Petreaca, Petros Grivas, Michael Thomas Schweizer, Celestia S. Higano, Yiyi Chen, Evan Y. Yu, Tomasz M. Beer: Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC), 2020 Genitourinary Cancers Symposium, J Clin Oncol 38, 2020.
84. Eric Jay Small, Shuang Zhao, William S. Chen, Haolong Li, Adam Foye, Martin Sjöström, Jun Jie Hua, Rahul Raj Aggarwal, **Joshi J. Alumkal**, Tomasz M. Beer, Martin Gleave, Matthew Rettig, Owen Witte, Primo Lara, Arul Chinnaiyan, Chris Maher, David A. Quigley, Felix Y Feng: The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT), 2020 ASCO Virtual Scientific Program, Virtual, J Clin Oncol, 38, 2021.
85. Martin Sjöström, Shuang Zhao, Eric Jay Small, Yuhong Ning, Corinne Maurice-Dror, Adam Foye, Jun Jie T. Hua, Haolong Li, Tomasz M. Beer, Christopher P. Evans, Matthew Rettig, Kim N. Chi, **Joshi J. Alumkal**, Rahul Raj Aggarwal, Alan Ashworth, Samuel Levy, Housheng H. He, Alexander W. Wyatt, David A. Quigley, Felix Y Feng: 5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC, 2021 Genitourinary Cancers Symposium, Virtual, J Clin Oncol, 39, 2021.